

## Prof. YUSUF YILMAZ

### Personal Information

**Email:** yusuf.yilmaz@erdogan.edu.tr

**Other Email:** dryusufyilmaz@gmail.com

**Web:** <https://avesis.erdogan.edu.tr/yusuf.yilmaz>

### International Researcher IDs

ScholarID: -xUdXf8AAAAJ

ORCID: 0000-0003-4518-5283

Publons / Web Of Science ResearcherID: K-6651-2012

ScopusID: 22936014300

Yoksis Researcher ID: 187733

### Biography

1978 yılında Rize’de doğan Yusuf Yılmaz 1996 yılında İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi’ni kazanarak dereceyle mezun olma başarısını göstererek 2002 yılında ‘Tıp Doktoru’ ünvanını almıştır. Aynı yıl tıpta uzmanlık sınavını kazanarak Uludağ Üniversitesi Tıp Fakültesi’ne girmiş, 2007 yılında ‘İç Hastalıkları Uzmanı’ olmuştur. Kısa bir süre zorunlu hizmet görevini yerine getirerek 2008 yılında kazandığı yan dal sınavı ile Marmara Üniversitesi Tıp Fakültesi Gastroenteroloji Bilim Dalı’nda yan dal uzmanlık eğitimine başlamıştır. 2011 yılında ‘Gastroenteroloji Uzmanı’ da olan ve aynı yıl Doçentlik sınavını da başarıyla veren Yusuf Yılmaz 2012 yılında Marmara Üniversitesi Tıp Fakültesi’ne ‘Öğretim Üyesi’ olarak atanmıştır. 2017 yılında tıp fakültesine atanan en genç ‘Profesör’ olmuştur. 2018 yılında dünyada ‘Tıp Bilimine Yön Veren 100 Türk’ arasına girmiştir.

Prof. Dr. Yusuf Yılmaz’ın uluslararası yabancı dergilerde yayımlanmış 150’ye yakın bilimsel araştırması bulunmaktadır. Uluslararası bir kuruluş olan Webometrics 2016 verilerine göre Dr. Yusuf Yılmaz, Türkiye’deki tüm bilim insanları içerisinde (sadece tıp alanında değil) 223. sıraya yerleşme başarısına bu genç yaşında ulaşmıştır. Google Akademik 2018 verilerine göre >30 h endeksi ve 4000 alıntılanma sayısı ile ülkemizin en iyi akademisyenleri arasında gösterilmektedir.

Yüksek özverili çalışmaları sayesinde alanında sadece dünyaca ünlü bilim insanlarının davet edilerek derlemelerinin yayımlandığı prestijli dergilerde yazar olma başarısını göstermiştir. Bütün bu başarılar sayesinde uluslararası NASH komitesine seçilen Avrupa’dan sayılı birkaç bilim insanından biridir. Ayrıca Avrupa Karaciğer Araştırmaları Derneği, Amerikan Karaciğer Araştırmaları Derneği, Amerikan Kronik Karaciğer Vakfı üyeliği bulunmaktadır.

Hepatology, Journal of Hepatology, Alimentary Pharmacology and Therapeutics, Diabetes Care , Metabolism gibi 50’den fazla uluslararası dergide hakemlik görevi bulunmaktadır. Çeşitli yıllarda en iyi hakem, en fazla alıntı yapılan araştırma, en çok alıntı yapılan derleme sahibi bilim insanı başarısını da göstermiştir.

Türkiye’de Fibroscan kullanımında en deneyimli kişi olan Prof. Dr. Yusuf Yılmaz, bu deneyimini gerek yurt içinde gerekse yurt dışında hekimlere yönelik eğitim kurslarıyla meslektaşlarıyla paylaşmaktadır.

### Education Information

Post Doctorate of Medicine, Marmara University, School Of Medicine, Turkey 2008 - 2011

Expertise In Medicine, Uludağ Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2002 - 2007

Undergraduate, Istanbul University, Cerrahpaşa Tıp Fakültesi, Turkey 1996 - 2002

## Foreign Languages

English, C1 Advanced

## Research Areas

Medicine, Internal Medicine Sciences, Internal Diseases , Gastroenterology and Hepatology

## Academic Titles / Tasks

Professor, Marmara University, School Of Medicine, Internal Medical Sciences, 2017 - Continues

## Academic and Administrative Experience

Rector, Recep Tayyip Erdogan University, Rektörlük, 2022 - Continues

Director of The Institution, Marmara University, Institute Of Gastroenterology, 2014 - 2022

## Advising Theses

Yılmaz Y., OBEZ HASTALARDA KARACİĞER YAĞLANMASININ VE FİBROZİSİNİN FİBROSCAN İLE NONİNVAZİV OLARAK DEĞERLENDİRİLMESİ, Expertise In Medicine, A.AVCU(Student), 2020

Yılmaz Y., Biyopsi kanıtlı non-alkolik yağlı karaciğer hastalığı bulunan bireylerde tip 2 diabetes mellitus, metabolik sendrom ve obezite prevalansının değerlendirilmesi, Expertise In Medicine, H.JAFAROVA(Student), 2019

Yılmaz Y., Nonalkolik karaciğer yağlanması bulunan hastalarda aterosklerozun ve karaciğer sertliğinin noninvazifdeğerlendirilmesi, Expertise In Medicine, B.Ören(Student), 2019

Güneş F. E., Yılmaz Y., Alkolik olmayan karaciğer yağlanması olan hastalarda bağırsaktaki faecalibacterium prausnitzii ve eubacterium rectale bakterilerinin değişimlerinin uygulanan diyet modeli ile ilişkilendirilmesi, Postgraduate, E.ÖĞÜZ(Student), 2019

Yılmaz Y., Fibroscan'ın nonalkolik yağlı karaciğer hastalığındaki tanısal performansının değerlendirilmesi, Expertise In Medicine, F.JAFAROV(Student), 2019

Yılmaz Y., Fibroscan'ın nonalkolik yağlı karaciğer hastalığındaki tanısal performansının değerlendirilmesi, Expertise In Medicine, F.Jafarov(Student), 2019

Tüfekçi Alphan M. E., Yılmaz Y., Normal kilolu non-alkolik yağlı karaciğer hastalığı olan bireylerde tıbbi beslenme tedavisinin etkinliğinin değerlendirilmesi, Doctorate, P.HAMURCU(Student), 2018

Yılmaz Y., Tip 2 diyabetli hastalarda karaciğer sertliğinin ve yağlanması Fibroscan ile saptanması, Expertise In Medicine, M.Demir(Student), 2018

YILMAZ Y., Nonalkolik yağlı karaciğerli hastalarda ileri evre fibrozisin saptanmasında noninvaziv yeni bir yöntem olan fibrometernin vcte'nin tanısal performansı, Expertise In Medicine, E.DİNÇSES(Student), 2015

Yılmaz Y., Non-alkolik yağlı karaciğerli hastalarda ileri evre fibrozisin saptanmasında non-invaziv fibrozis testlerinin tanısal performansı, Expertise In Medicine, C.FIRAT(Student), 2015

Yılmaz Y., Nonalkolik yağlı karaciğerli hastalarda ileri evre fibrozisin saptanmasında noninvaziv yeni bir yöntem olan fibrometer VCTE'nin tanısal performansı, Expertise In Medicine, E.DİNÇSES(Student), 2015

Yılmaz Y., Nonalkolik yağlı karaciğer hastalığında fibrozisin noninvaziv yöntemlerle araştırılması, Expertise In Medicine, U.EMRE(Student), 2014

## Jury Memberships

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Letter: Metabolic Dysfunction–Associated Steatotic Liver Disease in Primary Biliary Cholangitis—Friend, Foe or Red Herring?**  
Ergenc I., YILMAZ Y.  
Alimentary Pharmacology and Therapeutics, vol.60, no.11-12, pp.1641-1642, 2024 (SCI-Expanded)
- II. **The MAFLD definition identifies three homogenous groups of patients**  
Pan Z., YILMAZ Y., Al-Busafi S. A., Eslam M.  
Liver International, vol.44, no.12, pp.3287-3289, 2024 (SCI-Expanded)
- III. **Postbiotics as Antiinflammatory and Immune-Modulating Bioactive Compounds in Metabolic Dysfunction-Associated Steatotic Liver Disease**  
YILMAZ Y.  
Molecular Nutrition and Food Research, vol.68, no.23, 2024 (SCI-Expanded)
- IV. **Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals**  
Au K., Zheng M., Lee W., Ghanem O. M., Mahawar K., Shabbir A., le Roux C. W., Targher G., Byrne C. D., YILMAZ Y., et al.  
Current Obesity Reports, vol.13, no.4, pp.818-830, 2024 (SCI-Expanded)
- V. **Metabolic dysfunction associated fatty liver disease in healthy weight individuals**  
Méndez-Sánchez N., Brouwer W. P., Lammert F., YILMAZ Y.  
Hepatology International, vol.18, no.Suppl 2, pp.884-896, 2024 (SCI-Expanded)
- VI. **Impact of Comorbid Polycystic Ovary Syndrome on Clinical and Laboratory Parameters in Female Adolescents with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study**  
Keskin M., Arsoy H. A., Kara O., SARANDÖL E., Koca N., YILMAZ Y.  
Journal of Clinical Medicine, vol.13, no.19, 2024 (SCI-Expanded)
- VII. **Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2–F3 fibrosis**  
YILMAZ Y.  
Alimentary Pharmacology and Therapeutics, vol.60, no.7, pp.974-975, 2024 (SCI-Expanded)
- VIII. **Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma**  
Adali G., Aykut H., Bilgic N. M., YILMAZ Y.  
Heliyon, vol.10, no.18, 2024 (SCI-Expanded)
- IX. **Prevalence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis in Türkiye: A forensic autopsy study**  
Ergenc I., Kara E., Yilmaz M. E., DEMİRTAŞ C. Ö., Keklikkiran C., Das T., BÜYÜK Y., ÇELİKEL Ç., Asliyukse H., YILMAZ Y.  
Heliyon, vol.10, no.15, 2024 (SCI-Expanded)
- X. **Diagnostic accuracy of non-invasive tests to screen for at-risk MASH—An individual participant data meta-analysis**  
Mózes F. E., Lee J. A., Vali Y., Selvaraj E. A., Jayaswal A. N. A., Boursier J., de Lédinghen V., Lupşor-Platon M., YILMAZ Y., Chan W., et al.  
Liver International, vol.44, no.8, pp.1872-1885, 2024 (SCI-Expanded)
- XI. **A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease.**  
Zhang H., Targher G., Byrne C. D., Kim S. U., Wong V. W., Valenti L., Glickman M., Ponce J., Mantzoros C. S., Crespo J., et al.  
Hepatology international, vol.18, no.4, pp.1178-1201, 2024 (SCI-Expanded)

- XII. **The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease**  
Younossi Z. M., AlQahtani S. A., Funuyet-Salas J., Romero-Gómez M., YILMAZ Y., Keklikkiran C., Alswat K., Yu M., Liu C., Fan J., et al.  
JHEP Reports, vol.6, no.7, 2024 (SCI-Expanded)
- XIII. **Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology.**  
Ratziu V., Yilmaz Y., Lazas D., Friedman S. L., Lackner C., Behling C., Cummings O. W., Chen L., Petitjean M., Gilgun-Sherki Y., et al.  
Hepatology (Baltimore, Md.), 2024 (SCI-Expanded)
- XIV. **Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt**  
Alqahtani S. A., YILMAZ Y., El-Kassas M., Alswat K., Sanai F., AlZahrani M., Abaalkhail F., AlShaikh M., Al-Hamoudi W. K., Nader F., et al.  
Journal of Viral Hepatitis, vol.31, no.6, pp.300-308, 2024 (SCI-Expanded)
- XV. **Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa**  
Younossi Z. M., Golabi P., Paik J., Owrangi S., YILMAZ Y., El-Kassas M., Alswat K., Alqahtani S. A.  
Liver International, vol.44, no.4, pp.1061-1070, 2024 (SCI-Expanded)
- XVI. **Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: Results from a single-center biopsy study**  
Kaya E., YILMAZ Y.  
Chinese Medical Journal, vol.137, no.5, pp.616-618, 2024 (SCI-Expanded)
- XVII. **Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease**  
Younossi Z. M., Alqahtani S. A., Alswat K., YILMAZ Y., Keklikkiran C., Funuyet-Salas J., Romero-Gómez M., Fan J., Zheng M., El-Kassas M., et al.  
Journal of Hepatology, vol.80, no.3, pp.419-430, 2024 (SCI-Expanded)
- XVIII. **A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.**  
Hirschfield G. M., Bowlus C. L., Mayo M. J., Kremer A. E., Vierling J. M., Kowdley K. V., Levy C., Villamil A., Ladrón De Guevara Cetina A. L., Janczewska E., et al.  
The New England journal of medicine, vol.390, no.9, pp.783-794, 2024 (SCI-Expanded)
- XIX. **The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement.**  
Hagström H., Adams L. A., Allen A. M., Byrne C. D., Chang Y., Duseja A., Grønbaek H., Ismail M. H., Jepsen P., Kanwal F., et al.  
Hepatology communications, vol.8, no.2, 2024 (SCI-Expanded)
- XX. **Association of Metabolic Dysfunction-Associated Fatty Liver Disease with Cognitive Impairment and All-Cause Dementia: A Comprehensive Review**  
Kaya E., YILMAZ Y.  
Turkish Journal of Gastroenterology, vol.35, no.2, pp.76-82, 2024 (SCI-Expanded)
- XXI. **Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: One size fits all this time**  
El-Kassas M., Alswat K., Tharwat M., Labidi A., Medhat M. A., Sanai F. M., Benazzouz M., Tumi A., YILMAZ Y., Elzouki A.  
Journal of Hepatology, vol.80, no.2, 2024 (SCI-Expanded)
- XXII. **Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes**  
Çebi M., Yilmaz Y.  
Frontiers in Immunology, vol.15, 2024 (SCI-Expanded)
- XXIII. **Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease**

- Feng G., Valenti L., Wong V. W., Fouad Y. M., YILMAZ Y., Kim W., Sebastiani G., Younossi Z. M., Hernandez-Gea V., Zheng M.  
Nature Reviews Gastroenterology and Hepatology, vol.21, no.1, pp.46-56, 2024 (SCI-Expanded)
- XXIV. **Decoding 17-Beta-hydroxysteroid Dehydrogenase 13: A Multifaceted Perspective on Its Role in Hepatic Steatosis and Associated Disorders**  
DEMİRTAŞ C. Ö., YILMAZ Y.  
Journal of Clinical and Translational Hepatology, vol.12, no.10, pp.857-864, 2024 (SCI-Expanded)
- XXV. **Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction**  
Kaya E., YILMAZ Y., Alkhouri N.  
Expert Opinion on Investigational Drugs, vol.33, no.12, pp.1167-1176, 2024 (SCI-Expanded)
- XXVI. **Brushing your teeth may be good for your liver: Linking oral health to non-alcoholic fatty liver disease**  
YILMAZ Y.  
Annals of Hepatology, vol.28, no.6, 2023 (SCI-Expanded)
- XXVII. **Can Frequent Toothbrushing Reduce the Risk of Cirrhosis among Patients with Non-alcoholic Fatty Liver Disease? Hints from a Registry-based Study.**  
Keklikkiran C., Stepanova M., Younossi Z., Yilmaz Y.  
Digestive diseases (Basel, Switzerland), 2023 (SCI-Expanded)
- XXVIII. **A global research priority agenda to advance public health responses to fatty liver disease.**  
Lazarus J. V., Mark H. E., Allen A. M., Arab J. P., Carrieri P., Nouredin M., Alazawi W., Alkhouri N., Alqahtani S. A., Arrese M., et al.  
Journal of hepatology, 2023 (SCI-Expanded)
- XXIX. **A multi-society Delphi consensus statement on new fatty liver disease nomenclature.**  
Rinella M. E., Lazarus J. V., Ratziu V., Francque S. M., Sanyal A. J., Kanwal F., Romero D., Abdelmalek M. F., Anstee Q. M., Arab J. P., et al.  
Journal of hepatology, 2023 (SCI-Expanded)
- XXX. **A multi-society Delphi consensus statement on new fatty liver disease nomenclature.**  
Rinella M. E., Lazarus J. V., Ratziu V., Francque S. M., Sanyal A. J., Kanwal F., Romero D., Abdelmalek M. F., Anstee Q. M., Arab J. P., et al.  
Annals of hepatology, pp.101133, 2023 (SCI-Expanded)
- XXXI. **An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease**  
Sun D., Targher G., Byrne C. D., Wheeler D. C., Wong V. W., Fan J., Tilg H., Yuan W., Wanner C., Gao X., et al.  
HEPATOBIILIARY SURGERY AND NUTRITION, vol.12, no.3, 2023 (SCI-Expanded)
- XXXII. **Asia-Pacific association for study of liver guidelines on management of ascites in liver disease.**  
Singh V., De A., Mehtani R., Angeli P., Maiwall R., Satapathy S., Singal A. K., Saraya A., Sharma B. C., Eapen C. E., et al.  
Hepatology international, 2023 (SCI-Expanded)
- XXXIII. **An international multidisciplinary consensus statement on MAFLD and the risk of CVD.**  
Zhou X., Targher G., Byrne C. D., Somers V., Kim S. U., Chahal C. A. A., Wong V. W., Cai J., Shapiro M. D., Eslam M., et al.  
Hepatology international, pp.1-19, 2023 (SCI-Expanded)
- XXXIV. **Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study.**  
Anstee Q. M., Lucas K. J., Francque S., Abdelmalek M. F., Sanyal A. J., Ratziu V., Gadano A. C., Rinella M., Charlton M., Loomba R., et al.  
Hepatology (Baltimore, Md.), 2023 (SCI-Expanded)
- XXXV. **Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease**  
Pan Q., Fan J., Yilmaz Y.  
CLINICS IN LIVER DISEASE, vol.27, no.00, pp.317-332, 2023 (SCI-Expanded)
- XXXVI. **Geographical similarity and differences in the burden and genetic predisposition of NAFLD**  
Yip T. C., Vilar-Gomez E., Petta S., Yilmaz Y., Wong G. L., Adams L. A., De Lédinghen V., Sookoian S., Wong V. W.  
HEPATOLOGY, vol.77, no.4, pp.1404-1427, 2023 (SCI-Expanded)

- XXXVII. **Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry (TM)**  
Younossi Z. M., Yu M., Yilmaz Y., Alswat K. A., Buti M., Fernandez M. I. C., Papatheodoridis G., Hamid S. S., El-Kassas M., Chan W. K., et al.  
JOURNAL OF VIRAL HEPATITIS, vol.30, no.4, pp.335-344, 2023 (SCI-Expanded)
- XXXVIII. **Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.**  
Pennisi G., Enea M., Falco V., Aithal G. P., Palaniyappan N., Yilmaz Y., Boursier J., Cassinotto C., De Lédinghen V., Chan W. K., et al.  
Hepatology (Baltimore, Md.), 2023 (SCI-Expanded)
- XXXIX. **Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study.**  
Zhang H., Rios R. S., Boursier J., Anty R., Chan W., George J., Yilmaz Y., Wong V. W., Fan J., Dufour J., et al.  
Chinese medical journal, vol.136, pp.341-350, 2023 (SCI-Expanded)
- XL. **Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.**  
Sanyal A. J., Foucquier J., Younossi Z. M., Harrison S. A., Newsome P. N., Chan W., Yilmaz Y., De Ledinghen V., Costentin C., Zheng M., et al.  
Journal of hepatology, vol.78, no.2, pp.247-259, 2023 (SCI-Expanded)
- XLI. **Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study.**  
Yilmaz Y., Toraman A. E., Alp C., Doğan Z., Keklikkiran C., Stepanova M., Younossi Z.  
Alimentary pharmacology & therapeutics, vol.57, no.2, pp.215-223, 2023 (SCI-Expanded)
- XLII. **Editorial: changes of health-related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD-authors' reply.**  
Yilmaz Y., Younossi Z.  
Alimentary pharmacology & therapeutics, vol.57, no.2, pp.259-260, 2023 (SCI-Expanded)
- XLIII. **Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice**  
Lazarus J. V., Castera L., Mark H. E., Allen A. M., Adams L. A., Anstee Q. M., Arrese M., Alqahtani S. A., Bugianesi E., Colombo M., et al.  
JHEP REPORTS, vol.5, no.1, pp.100596-100601, 2023 (SCI-Expanded)
- XLIV. **Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease**  
Kaya E., Yilmaz Y.  
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, vol.13, pp.1-13, 2022 (SCI-Expanded)
- XLV. **The effects of dietary intervention on fibrosis and biochemical parameters in metabolic-associated fatty liver disease.**  
Ozlu T., Yilmaz Y., Gunes F. E.  
Minerva gastroenterology, vol.68, pp.426-433, 2022 (SCI-Expanded)
- XLVI. **Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry**  
Younossi Z. M., Yu M., El-Kassas M., Esmat G., Fernandez M. I. C., Buti M., Papatheodoridis G., Yilmaz Y., Isakov V., Duseja A., et al.  
JOURNAL OF VIRAL HEPATITIS, vol.29, no.11, pp.1015-1025, 2022 (SCI-Expanded)
- XLVII. **DEPRESSION AND EMOTIONAL DISTRESS IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (TM) (GLR (TM))**  
Younossi Z. M., Stepanova M., Fernandez M. I. C., Yilmaz Y., Yu M., El Kassas M., Esmat G., Isakov V. A., Wong V. W., Eguchi Y., et al.  
HEPATOLOGY, vol.76, 2022 (SCI-Expanded)
- XLVIII. **The impact of the COVID-19 pandemic on patients with chronic liver disease: Results from the Global**

## **Liver Registry**

Younossi Z. M., Yilmaz Y., El-Kassas M., Duseja A., Hamid S., Esmat G., Mendez-Sanchez N., Chan W. K., Singal A. K., Lam B., et al.

HEPATOLOGY COMMUNICATIONS, vol.6, no.10, pp.2860-2866, 2022 (SCI-Expanded)

- XLIX. **Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry.**  
Younossi Z. M., Yilmaz Y., Yu M., Wai-Sun Wong V., Fernandez M. C., Isakov V. A., Duseja A. K., Mendez-Sanchez N., Eguchi Y., Bugianesi E., et al.  
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol.20, pp.2296-2312, 2022 (SCI-Expanded)
- L. **HEPATOCTE APOPTOSIS FRAGMENT PRODUCT CYTOKERATIN-18 M30 AND NON-ALCOHOLIC STEATOHEPATITIS RISK PREDICTION: AN INTERNATIONAL REGISTRY STUDY**  
Zhang H., Rios R. S., Boursier J., Anty R., Chan W., George J., Yilmaz Y., Wong V. W., Sookoian S., Fan J., et al.  
GUT, vol.71, 2022 (SCI-Expanded)
- LI. **Lean non-alcoholic fatty liver disease patients from the global NASH registry**  
Younossi Z., YILMAZ Y., Yu M., Wong V. W., Castellanos-Fernandez M., Isakov V., Duseja A. K., Mendez-Sanchez N., Eguchi Y., Bugianesi E., et al.  
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- LII. **Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease**  
Younossi Z., YILMAZ Y., El Kassas M., Duseja A. K., Hamid S. S., Esmat G., Mendez-Sanchez N., Chan W., Singal A., Ong J., et al.  
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- LIII. **Multimodality assessment of hepatic fibrosis: ranked paired reading and artificial intelligence identifies fibrosis improvement with aramchol missed by conventional staging**  
Ratziu V., Yilmaz Y., Lazas D., Friedman S., Lackner C., Behling C., Cummings O., Chen L., Petitjean M., Gilgun-Sherki Y., et al.  
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- LIV. **Higher daily Aramchol dose results in higher effect size in fibrosis improvement in the ARMOR study open label part**  
Ratziu V., YILMAZ Y., Lazas D., Friedman S., Hayardeny L., Kadosh S., Gorfine T., Sanyal A.  
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- LV. **A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease.**  
Younossi Z. M., Ong J. P., Takahashi H., Yilmaz Y., Eguchi Y., El Kassas M., Buti M., Diago M., Zheng M., Fan J., et al.  
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol.20, 2022 (SCI-Expanded)
- LVI. **Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.**  
Mózes F. E., Lee J. A., Selvaraj E. A., Jayaswal A. N. A., Trauner M., Boursier J., Fournier C., Staufer K., Stauber R. E., Bugianesi E., et al.  
Gut, vol.71, pp.1006-1019, 2022 (SCI-Expanded)
- LVII. **Global multi-stakeholder endorsement of the MAFLD definition**  
Méndez-Sánchez N., Bugianesi E., Gish R. G., Lammert F., Tilg H., Nguyen M. H., Sarin S. K., Fabrellas N., Zelber-Sagi S., Fan J., et al.  
The Lancet Gastroenterology and Hepatology, vol.7, no.5, pp.388-390, 2022 (SCI-Expanded)
- LVIII. **Fibroscan detection of fatty liver and liver fibrosis in patients with systemic lupus erythematosus**  
Yetginoglu O., Atas D. B., Yilmaz Y., Velioglu A., Arıkan H., Alibaz-Oner F., Direskeneli H., Tuglular S., Ascioglu E.  
Lupus, vol.31, no.6, pp.723-729, 2022 (SCI-Expanded)
- LIX. **The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?**  
Lazarus J. V., Mark H. E., Villota-Rivas M., Palayew A., Carrieri P., Colombo M., Ekstedt M., Esmat G., George J.,

Marchesini G., et al.

Journal of hepatology, vol.76, pp.771-780, 2022 (SCI-Expanded)

- LX. **Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver**  
Kaya E., Yilmaz Y.  
Journal of Clinical and Translational Hepatology, vol.10, no.2, pp.329-338, 2022 (SCI-Expanded)
- LXI. **Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals.**  
Eren F., Kaya E., Yilmaz Y.  
European journal of gastroenterology & hepatology, vol.34, pp.98-103, 2022 (SCI-Expanded)
- LXII. **Advancing the global public health agenda for NAFLD: a consensus statement**  
Lazarus J., Mark H. E., Anstee Q. M., Arab J. P., Batterham R. L., Castera L., Cortez-Pinto H., Crespo J., Cusi K., Dirac M. A., et al.  
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, vol.19, pp.60-78, 2022 (SCI-Expanded)
- LXIII. **Macro- and micronutrients in metabolic (dysfunction) associated fatty liver disease: association between advanced fibrosis and high dietary intake of cholesterol/saturated fatty acids.**  
Guveli H., Kenger E. B., Ozlu T., Kaya E., Yilmaz Y.  
European journal of gastroenterology & hepatology, vol.33, 2021 (SCI-Expanded)
- LXIV. **acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study.**  
Wu X., Zheng K. I., Boursier J., Chan W., Yilmaz Y., Romero-Gómez M., El Kassas M., Targher G., Byrne C. D., Huang Z., et al.  
EClinicalMedicine, vol.41, pp.101145, 2021 (SCI-Expanded)
- LXV. **COVID-19 PANDEMIC AND CHRONIC LIVER DISEASE (CLD)**  
Younossi Z. M., YILMAZ Y., El Kassas M., Duseja A. K., Hamid S. S., Esmat G., Mendez-Sanchez N., Chan W. K., Singal A. K., Lam B. P., et al.  
HEPATOLOGY, vol.74, 2021 (SCI-Expanded)
- LXVI. **FATIGUE AND NON-ALCOHOLIC FATTY LIVER DISEASE: DATA FROM THE GLOBAL NASH REGISTRY**  
Younossi Z. M., YILMAZ Y., Wong V. W., Fernandez M. I. C., Bugianesi E., Burra P., Yu M., Chan W. K., Isakov V. A., Duseja A. K., et al.  
HEPATOLOGY, vol.74, 2021 (SCI-Expanded)
- LXVII. **A NOVEL STUDY DESIGN WITH ARAMCHOL EXPLORING THE KINETICS AND INTER-RELATIONS OF HISTOLOGICAL OUTCOME MEASURES AND NON-INVASIVE TESTS ASSOCIATED WITH NASH AND FIBROSIS FOR VARIABLE TREATMENT DURATIONS**  
Ratziu V., YILMAZ Y., Lazas D., De Guevara L. L., Kadosh S., Gorfine T., Sanyal A. J.  
HEPATOLOGY, vol.74, 2021 (SCI-Expanded)
- LXVIII. **Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study**  
Demirtas C. O., Keklikkiran C., Ergenc I., Erturk Sengel B., Eskidemir G., Cinel I., Odabasi Z., Korten V., Yilmaz Y.  
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.75, no.9, 2021 (SCI-Expanded)
- LXIX. **Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease**  
KANİ H. T., DEMİRTAŞ C. Ö., KEKLİKKIRAN Ç., Ergenc I., Mehdiyev S., AKDENİZ E., YILMAZ Y.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.8, pp.661-666, 2021 (SCI-Expanded)
- LXX. **Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement.**  
Hagström H., Adams L. A., Allen A. M., Byrne C. D., Chang Y., Grønbaek H., Ismail M., Jepsen P., Kanwal F., Kramer J., et al.  
Hepatology (Baltimore, Md.), vol.74, pp.474-482, 2021 (SCI-Expanded)
- LXXI. **Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosis**



- Mozes F., Lee J., Selvaraj E., Jayaswal A., Trauner M., Boursier J., Fournier C., Staufer K., Stauber R., Bugianesi E., et al.  
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- LXXII. **The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry**  
Younossi Z., YILMAZ Y., El-Kassas M., Duseja A. K., Hamid S. S., Esmat G., Mendez-Sanchez N., Chan W., Singal A., Lam B., et al.  
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- LXXIII. **Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease**  
Younossi Z., Harrison S., Newsome P. N., Chan W., YILMAZ Y., de Ledinghen V., Costentin C., Zheng M., Wong V. W., Elkhatab M., et al.  
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- LXXIV. **Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease—simply associated or more complicated?**  
Demirtas C. O., Yilmaz Y.  
Alimentary pharmacology & therapeutics, vol.53, pp.1228-1229, 2021 (SCI-Expanded)
- LXXV. **Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic**  
AVCU A., Kaya E., YILMAZ Y.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.5, pp.466-472, 2021 (SCI-Expanded)
- LXXVI. **FIBROSCAN DETECTION OF FATTY LIVER AND LIVER FIBROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS**  
YETGİNOĞLU Ö., Atas D. B., VELİOĞLU A., ARIKAN İ. H., YILMAZ Y., ALİBAZ ÖNER F., DİRESKENELİ R. H., TUĞLULAR Z. S., AŞICIOĞLU E.  
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.36, pp.172, 2021 (SCI-Expanded)
- LXXVII. **A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD.**  
Yilmaz Y., Byrne C., Musso G.  
Expert review of gastroenterology & hepatology, vol.15, pp.345-352, 2021 (SCI-Expanded)
- LXXVIII. **Recommendations for Reopening Endoscopy Units in Turkey: A Set-up Plan from a Tertiary Center in Istanbul.**  
Demirtas C. Ö., Keklikkiran Ç., Mehdiyev S., Ergenç İ., Özen Alahdab Y., Gündüz F., Yılmaz Y., Atuş Ö., Özdoğan O. C.  
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.32, pp.113-115, 2021 (SCI-Expanded)
- LXXIX. **The case for simplifying and using absolute targets for viral hepatitis elimination goals.**  
Razavi H., Blach S., Razavi-Shearer D., Polaris O.  
Journal of viral hepatitis, vol.28, pp.12-19, 2021 (SCI-Expanded)
- LXXX. **Letter: the use of Fibrosis-4 score in primary care and diabetology practices—Occam's razor applied to advanced fibrosis screening.**  
Yilmaz Y., Kaya E., Eren F.  
Alimentary pharmacology & therapeutics, vol.52, pp.1759-1760, 2020 (SCI-Expanded)
- LXXXI. **The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease**  
Eslam M., Sarin S., Wong V., Fan J., Kawaguchi T., Ahn S., Zheng M., Shiha G., Yilmaz Y., Gani R., et al.  
HEPATOLOGY INTERNATIONAL, vol.14, no.6, pp.889-919, 2020 (SCI-Expanded)
- LXXXII. **Effect of carbon dioxide versus room air insufflation on post-colonoscopy pain: A prospective, randomized, controlled study.**  
Gündüz F., Kani H., Chang S., Akdeniz E., Eren F., Yılmaz Y., Alahdab Y.  
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.31, pp.676-680, 2020 (SCI-Expanded)

- LXXXIII. **Impact of aerobic training with and without whole-body vibration training on metabolic features and quality of life in non-alcoholic fatty liver disease patients.**  
Saldıran T, Mutluay F, Yağcı İ, Yılmaz Y.  
Annales d'endocrinologie, vol.81, pp.493-499, 2020 (SCI-Expanded)
- LXXXIV. **Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients.**  
Hamurcu V, Kaya E, Alphan E, Yılmaz Y.  
European journal of gastroenterology & hepatology, vol.32, pp.1352-1357, 2020 (SCI-Expanded)
- LXXXV. **Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD.**  
Sun D, Ye F, Kani H, Yang J, Zheng K, Zhang H, Targher G, Byrne C, Chen Y, Yuan W., et al.  
Diabetes & metabolism, vol.46, pp.288-295, 2020 (SCI-Expanded)
- LXXXVI. **External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients**  
Demirtas C., Gunduz F., Kani H., Keklikkiran C., Alahdab Y., Yılmaz Y., Duman D., Atug O., Giral A., Aslan R., et al.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.32, no.7, pp.882-888, 2020 (SCI-Expanded)
- LXXXVII. **Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease.**  
Kaya E., Bakir A., Kani H., Demirtas C., Keklikkiran C., Yılmaz Y.  
Gut and liver, vol.14, pp.486-491, 2020 (SCI-Expanded)
- LXXXVIII. **A new definition for metabolic associated fatty liver disease: an international expert consensus statement.**  
Eslam M., Newsome P., Anstee Q., Targher G., Gomez M., Zelber-Sagi S., Wong V., Dufour J., Schattenberg J., Arrese M., et al.  
Journal of hepatology, vol.73, pp.202-209, 2020 (SCI-Expanded)
- LXXXIX. **MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.**  
Eslam M., Sanyal A., George J., International C.  
Gastroenterology, vol.158, 2020 (SCI-Expanded)
- XC. **The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study**  
Jafarov F., Kaya E., Bakir A., Eren F., Yılmaz Y.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.32, pp.642-649, 2020 (SCI-Expanded)
- XCI. **The interaction between current smoking and hemoglobin on the risk of advanced fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease.**  
Enc F., Ulasoglu C., Bakir A., Yılmaz Y.  
European journal of gastroenterology & hepatology, vol.32, pp.597-600, 2020 (SCI-Expanded)
- XCII. **FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.**  
Newsome P., Sasso M., Deeks J., Paredes A., Boursier J., Chan W., Yılmaz Y., Czernichow S., Zheng M., Wong V., et al.  
The lancet. Gastroenterology & hepatology, vol.5, pp.362-373, 2020 (SCI-Expanded)
- XCIII. **Letter: the perilous road to a functional cure for hepatitis B infection.**  
Yılmaz Y.  
Alimentary pharmacology & therapeutics, vol.51, pp.577, 2020 (SCI-Expanded)
- XCIV. **Letter: a stepwise approach towards the screening of hepatic fibrosis in the general population.**  
Yılmaz Y.  
Alimentary pharmacology & therapeutics, vol.51, pp.669-670, 2020 (SCI-Expanded)
- XCV. **Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.**  
Alkayyali T., Qutranji L., Kaya E., Bakir A., Yılmaz Y.  
Acta diabetologica, 2020 (SCI-Expanded)

- XCVI. NFS Is Not a Marker of Nonalcoholic Fatty Liver Disease Per Se: What Is the True Relationship With CAD Complexity?**  
Yılmaz Y., Eren F.  
ANGIOLOGY, vol.71, pp.83-84, 2020 (SCI-Expanded)
- XCVII. Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study.**  
Bilgin B., Sunbul M., Kani H. T., Demirtas C., Keklikkiran C., Yılmaz Y.  
European journal of gastroenterology & hepatology, vol.32, pp.54-57, 2020 (SCI-Expanded)
- XCVIII. Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels.**  
Ulasoglu C., Enc F., Kaya E., Yılmaz Y.  
Journal of gastrointestinal and liver diseases : JGLD, vol.28, pp.427-431, 2019 (SCI-Expanded)
- XCIX. Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.**  
Tatar B., Köse Ş., Ergun N., Turken M., Onlen Y., Yılmaz Y., Akhan S.  
Revista da Associacao Medica Brasileira (1992), vol.65, pp.1470-1475, 2019 (SCI-Expanded)
- C. Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis**  
Hasturk B., Yılmaz Y., Eren F.  
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, vol.18, pp.463-475, 2019 (SCI-Expanded)
- CI. Comments on "The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease"**  
Yılmaz Y., Eren F.  
SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES, vol.29, no.6, pp.548, 2019 (SCI-Expanded)
- CII. Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter**  
Yılmaz Y., Eren F.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.31, no.12, pp.1601-1602, 2019 (SCI-Expanded)
- CIII. Hepatic fibrosis - and not steatosis - is the main determinant of arterial stiffness in non-alcoholic fatty liver disease**  
Yılmaz Y., Eren F.  
ATHEROSCLEROSIS, vol.290, pp.222-223, 2019 (SCI-Expanded)
- CIV. Non-alcoholic fatty liver disease: A growing public health problem in Turkey**  
Kaya E., YILMAZ Y.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.10, pp.865-871, 2019 (SCI-Expanded)
- CV. Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents**  
Kesen O., Kani H., Yanartaş Ö., Aykut U., Gök B., Gündüz F., Yılmaz Y., Özdoğan O. C., Özen A.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.9, pp.801-806, 2019 (SCI-Expanded)
- CVI. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease**  
Younossi Z. M., Stepanova M., Ong J., Yılmaz Y., Duseja A., Eguchi Y., El Kassas M., Castellanos-Fernandez M., George J., Jacobson I. M., et al.  
Clinical Gastroenterology and Hepatology, vol.17, pp.1625, 2019 (SCI-Expanded)
- CVII. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis**  
Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E., Wai-Sun Wong V., Yılmaz Y., George J., Fan J., et al.  
Hepatology, vol.69, pp.2672-2682, 2019 (SCI-Expanded)
- CVIII. Liver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease**

Dq S, Fang Zhoe Y, KANI H. T., Chen Fei Z., Pei Wu Z., Hong Lei M., Wen Yue L., Hao Yang Z., Xiao Dong W., Wei Jie Y., et al.

Journal Of Hepatology, vol.70, pp.787, 2019 (SCI-Expanded)

- CIX. **Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study**  
DEMİR M., Deyneli O, YILMAZ Y.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.3, pp.266-270, 2019 (SCI-Expanded)
- CX. **Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates**  
Younossi Z., Stepanova M., Ong J. P., Jacobson I. M., Bugianesi E., Duseja A., Eguchi Y., Wong V. W., Negro F., Yilmaz H. Y., et al.  
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.17, no.4, pp.748-758, 2019 (SCI-Expanded)
- CXI. **The optimal controlled attenuation parameter cut-offs in hepaticsteatosis grade differentiation by transient elastography(Fibroscan) in a sample of biopsy-proven non-alcoholic fatty liverdisease patients**  
Kaya E, BAKIR A., Sapmaz A. F., Kayyali T., Quatranji L., Çiftaslan A., Demirtas C. O., DEMİRTAŞ C. Ö., KANI H. T., YILMAZ Y.  
Hepatology International, vol.13, pp.196, 2019 (SCI-Expanded)
- CXII. **Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.**  
Yılmaz Y., Kani H. T., Demirtaş C., Kaya E., Sapmaz A., Qutranji L., Alkayyali T., Batun K., Batman M., Toy B., et al.  
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.30, pp.892-898, 2019 (SCI-Expanded)
- CXIII. **Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology**  
YILMAZ Y., EREN F.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.31, no.1, pp.43-46, 2019 (SCI-Expanded)
- CXIV. **Nonalcoholic Fatty Liver Disease(NAFLD) and Alcoholic Fatty Liver Disease(AFLD): The impact of Alcohol Comsumpt,on and Metabolic Syndrome on Mortality**  
Younossi Z., Maria S., Ong J., Yılmaz Y., Duseja A., Eguchi Y., Elkassas M., Castel L., Fernandez V., George J., et al.  
Hepatology, vol.68, pp.1, 2018 (SCI-Expanded)
- CXV. **THE SEQUENCE ANALYSIS OF NEW MITOCHONDRIALGENE, MOTS-C, IN PATIENTS WITH THE NON-ALCOHOLICSTEATOHEPATITIS**  
Önal O., Eren F., Yılmaz D., Göçmen T., Yılmaz Y.  
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, vol.6, pp.135, 2018 (SCI-Expanded)
- CXVI. **Development of multiplex single base primer extension assay for the detection of potential association between MTNR1B gene polymorphisms and NASH**  
Yılmaz D., Eren F., Göçmen T., Yılmaz Y.  
Journal Of Biotechnology, vol.280, pp.76, 2018 (SCI-Expanded)
- CXVII. **The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease**  
Ozturk K., Dogan T., Celikkanat S., Ozen A., Demirci H., Kurt O., Turker T., YILMAZ Y., Uygun A.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.30, no.4, pp.411-417, 2018 (SCI-Expanded)
- CXVIII. **The correlation between histopathologic steatosis/fibrosis and various non-invasive imagingand blood fibrosis indicators of overweight and obese children**  
Tutar E., Şahin Akkelle B., Kesici C. B., Yılmaz Y., Çelikel Ç., Ergelen R., Ertem Şahinoğlu D.  
Journal Of Pediatric Gastroenterology And Nutrition, vol.66, 2018 (SCI-Expanded)
- CXIX. **Transient elastography with controlled attenuation parameter in the assessment of hepatic steatosis and significant liver fibrosis in patients with scleroderma**  
Yılmaz Y., Kani H. T., Şahinkaya Y., Deliktaş İ., Mursaloğlu H. H., Aziziy M., İnanç G. N., Direskeneli R. H.  
Hepatology International, vol.12, 2018 (SCI-Expanded)
- CXX. **Recommendation for treatment of hepatitis C virus infection**  
KAYMAKOĞLU S., Koksall I., KAYMAKOĞLU S., Tabak F., Akarca U. S., Akbulut A., AKYÜZ F., Bodur H., ÇAĞATAY A. A.,

- Dincer D., et al.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, 2017 (SCI-Expanded)
- CXXI. **Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases**  
YILMAZ Y., EREN F.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, no.5, pp.327-328, 2017 (SCI-Expanded)
- CXXII. **The association of nonalcoholic fatty liver disease with genetic polymorphisms: A multicenter study**  
Uygun A., Ozturk K., Demirci H., Oztuna A., Eren F., Kozan S., Yılmaz Y., Kurt O., Turker T., Vatansever S., et al.  
European Journal of Gastroenterology and Hepatology, vol.29, pp.441-447, 2017 (SCI-Expanded)
- CXXIII. **Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter**  
Kaya E., Demir D., ÖZEN ALAHDAB Y., YILMAZ Y.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.28, no.11, pp.1264-1267, 2016 (SCI-Expanded)
- CXXIV. **Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis**  
ERGELEN R., YILMAZ Y., Asedov R., ÇELİKEL Ç., Akin H., BUĞDAYCI O., Altun E., TÜNEY D.  
ABDOMINAL RADIOLOGY, vol.41, no.8, pp.1505-1510, 2016 (SCI-Expanded)
- CXXV. **The role of active brown adipose tissue in human metabolism**  
Ozguven S., Ones T., Yılmaz Y., Turoglu H. T., Imeryuz N.  
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.43, no.2, pp.355-361, 2016 (SCI-Expanded)
- CXXVI. **Diagnostic Role of Colon Capsule Endoscopy in Patients with Optimal Colon Cleaning**  
Akyüz Ü., Yılmaz Y., Ince A. T., Kaya B., Pata C.  
Gastroenterology Research and Practice, vol.2016, 2016 (SCI-Expanded)
- CXXVII. **Is NAFLD different in absence of metabolic syndrome?**  
YILMAZ Y.  
CLINICAL DILEMMAS IN NON-ALCOHOLIC FATTY LIVER DISEASE, pp.44-49, 2016 (SCI-Expanded)
- CXXVIII. **Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease**  
Dincses E., YILMAZ Y.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.27, no.10, pp.1149-1153, 2015 (SCI-Expanded)
- CXXIX. **Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease**  
Sünbül M., Kivrak T., Durmus E., Akin H., Aydin Y., Ergelen R., Yılmaz Y., Agirbasli M.  
CARDIOVASCULAR THERAPEUTICS, vol.33, pp.294-299, 2015 (SCI-Expanded)
- CXXX. **Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease**  
Ozturk O., ÇOLAK Y., ŞENATEŞ E., YILMAZ Y., Ulasoglu C., Doganay L., Ozkanli S., Oltulu Y. M., Coskunpinar E., TUNCER İ.  
WORLD JOURNAL OF GASTROENTEROLOGY, vol.21, no.26, pp.8096-8102, 2015 (SCI-Expanded)
- CXXXI. **Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease**  
ERGELEN R., Akyuz U., Aydin Y., EREN F., YILMAZ Y.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.27, no.6, pp.667-671, 2015 (SCI-Expanded)
- CXXXII. **Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels**  
Akyuz U., Yesil A., YILMAZ Y.  
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.50, no.3, pp.341-346, 2015 (SCI-Expanded)

- CXXXIII. **Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease**  
Subasi C. F., Aykut U. E., YILMAZ Y.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.27, no.2, pp.137-141, 2015 (SCI-Expanded)
- CXXXIV. **No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects**  
Yonal O., EREN F., YILMAZ Y., ATUĞ Ö., Over H. H.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.25, no.6, pp.639-643, 2014 (SCI-Expanded)
- CXXXV. **Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness.**  
Sünbül M., Agirbasli M., Durmus E., Kivrak T., Akin H., Aydin Y., Ergelen R., Yilmaz Y.  
Atherosclerosis, vol.237, no.2, pp.490-3, 2014 (SCI-Expanded)
- CXXXVI. **Can Enhanced Autophagy Be Associated with Human Longevity? Serum Levels of the Autophagy Biomarker Beclin-1 Are Increased in Healthy Centenarians**  
Emanuele E., Minoretti P., Sanchis-Gomar F., Pareja-Galeano H., YILMAZ Y., Garatachea N., Lucia A.  
REJUVENATION RESEARCH, vol.17, no.6, pp.518-524, 2014 (SCI-Expanded)
- CXXXVII. **A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease**  
YILMAZ Y., EREN F.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.26, no.11, pp.1292-1295, 2014 (SCI-Expanded)
- CXXXVIII. **ARE PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE AT INCREASED RISK OF ASTHMA? - RESULTS FROM A TURKISH CROSS-SECTIONAL STUDY**  
Tasli B., YILMAZ Y.  
RESPIROLOGY, vol.19, pp.189, 2014 (SCI-Expanded)
- CXXXIX. **A comparison of FibroMeter (TM) NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease**  
Aykut U. E., Akyuz U., Yesil A., EREN F., Gerin F., ERGELEN R., ÇELİKEL Ç., YILMAZ Y.  
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.49, no.11, pp.1343-1348, 2014 (SCI-Expanded)
- CXL. **A Potential Treatment of Non-Alcoholic Fatty Liver Disease with SIRT1 Activators**  
ÇOLAK Y., Yesil A., MUTLU H. H., Cakili O. T., Ulasoglu C., ŞENATEŞ E., Takir M., Kostek O., YILMAZ Y., Enc F. Y., et al.  
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, vol.23, no.3, pp.311-319, 2014 (SCI-Expanded)
- CXLI. **Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis**  
Musso G., Gambino R., Tabibian J. H., Ekstedt M., Kechagias S., Hamaguchi M., Hultcrantz R., Hagstrom H., Yoon S. K., Charatcharoenwitthaya P., et al.  
PLOS MEDICINE, vol.11, no.7, 2014 (SCI-Expanded)
- CXLII. **Letter: gut microbiota modulation contributes to coffee's benefits for non-alcoholic fatty liver disease - authors' reply**  
Yesil A., Yilmaz Y.  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.39, no.12, pp.1442, 2014 (SCI-Expanded)
- CXLIII. **Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease**  
YILMAZ Y., Ayyildiz T., Akin H., ÇOLAK Y., Ozturk O., Senates E., TUNCER İ., Dolar E.  
GUT AND LIVER, vol.8, no.3, pp.313-317, 2014 (SCI-Expanded)
- CXLIV. **Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy**  
YILMAZ Y., Yesil A., Gerin F., ERGELEN R., Akin H., ÇELİKEL Ç., Imeryuz N.  
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.49, no.5, pp.611-616, 2014 (SCI-Expanded)
- CXLV. **Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease**

- YILMAZ Y., Senates E., Yesil A., ERGELEN R., ÇOLAK Y.  
JOURNAL OF DIABETES AND ITS COMPLICATIONS, vol.28, no.3, pp.328-331, 2014 (SCI-Expanded)
- CXLVI. **Obesity-Associated Nonalcoholic Fatty Liver Disease**  
YILMAZ Y., Younossi Z. M.  
CLINICS IN LIVER DISEASE, vol.18, no.1, pp.19-32, 2014 (SCI-Expanded)
- CXLVII. **Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease**  
Yesil A., Yilmaz Y.  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.38, no.9, pp.1038-1044, 2013 (SCI-Expanded)
- CXLVIII. **Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography**  
YILMAZ Y., ERGELEN R., Akin H., Imeryuz N.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.25, no.11, pp.1330-1334, 2013 (SCI-Expanded)
- CXLIX. **Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials**  
YILMAZ Y.  
CURRENT DRUG TARGETS, vol.14, no.11, pp.1357-1366, 2013 (SCI-Expanded)
- CL. **Liver disease and malnutrition**  
Purnak T., YILMAZ Y.  
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, vol.27, no.4, pp.619-629, 2013 (SCI-Expanded)
- CLI. **Assessment of endothelial function in patients with nonalcoholic fatty liver disease**  
Colak Y., Senates E., Yesil A., YILMAZ Y., Ozturk O., Doganay L., Coskunpinar E., Kahraman O. T., MESCİ B., Ulasoglu C., et al.  
ENDOCRINE, vol.43, no.1, pp.100-107, 2013 (SCI-Expanded)
- CLII. **Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease**  
YILMAZ Y., Ozturk O., Alandab Y., Senates E., ÇOLAK Y., Doganay H. L., Coskunpinar E., Oltulu Y. M., EREN F., ATUĞ Ö., et al.  
DIGESTIVE AND LIVER DISEASE, vol.45, no.1, pp.58-62, 2013 (SCI-Expanded)
- CLIII. **Letter: diagnostic accuracy of M30 levels for identifying patients with non-alcoholic steatohepatitis**  
Yilmaz Y.  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.37, no.2, pp.283, 2013 (SCI-Expanded)
- CLIV. **Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back**  
YILMAZ Y., ÇOLAK Y., Kurt R., Senates E., EREN F.  
TUMORI, vol.99, no.1, pp.10-16, 2013 (SCI-Expanded)
- CLV. **Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis**  
YILMAZ Y., EREN F.  
CLINICA CHIMICA ACTA, vol.414, pp.154-157, 2012 (SCI-Expanded)
- CLVI. **Hepatic expression and serum levels of syndecan 1 (CD 138) in patients with nonalcoholic fatty liver disease**  
YILMAZ Y., EREN F., ÇOLAK Y., Senates E., ÇELİKEL Ç., Imeryuz N.  
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.47, no.12, pp.1488-1493, 2012 (SCI-Expanded)
- CLVII. **Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?**  
Yilmaz Y.  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.36, no.9, pp.815-823, 2012 (SCI-Expanded)
- CLVIII. **Research update for articles published in EJCI in 2010**  
Aldbrecht C., Aigner E., Bellon J. M., Bouloukaki I., Bouzas-Mosquera A., Carrilho A. J. F., Chang K., Chattipakorn N., Chattipakorn S. C., Chen Y., et al.

- EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol.42, no.11, pp.1149-1164, 2012 (SCI-Expanded)
- CLIX. **Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease**  
YILMAZ Y.  
CLINICA CHIMICA ACTA, vol.413, pp.1190-1193, 2012 (SCI-Expanded)
- CLX. **Review article: non-alcoholic fatty liver disease and osteoporosis - clinical and molecular crosstalk**  
Yilmaz Y.  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.36, no.4, pp.345-352, 2012 (SCI-Expanded)
- CLXI. **Nonalcoholic Fatty Liver Disease: A Nutritional Approach**  
ÇOLAK Y., TUNCER İ., Senates E., Ozturk O., Doganay L., YILMAZ Y.  
METABOLIC SYNDROME AND RELATED DISORDERS, vol.10, no.3, pp.161-166, 2012 (SCI-Expanded)
- CLXII. **Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis**  
YILMAZ Y., Yonal O., Deyneli O., ÇELİKEL Ç., Kalayci C., DUMAN D.  
ACTA GASTRO-ENTEROLOGICA BELGICA, vol.75, no.2, pp.240-244, 2012 (SCI-Expanded)
- CLXIII. **Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease**  
Eren F., Kurt R., Ermis F., Atuğ Ö., Imeryuz N., Yılmaz Y.  
Clinical Biochemistry, vol.45, pp.655-658, 2012 (SCI-Expanded)
- CLXIV. **Review article: fructose in non-alcoholic fatty liver disease**  
Yilmaz Y.  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.35, pp.1135-1144, 2012 (SCI-Expanded)
- CLXV. **Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome**  
YILMAZ Y., Senates E., Ayyildiz T., Colak Y., Tuncer I., Ovunc A. O. K., Dolar E., Kalayci C.  
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol.42, no.4, pp.411-418, 2012 (SCI-Expanded)
- CLXVI. **Circulating vaspin and its relationship with insulin sensitivity, adiponectin and liver histology in subjects with non-alcoholic steatohepatitis**  
YILMAZ Y.  
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.47, no.4, pp.489-490, 2012 (SCI-Expanded)
- CLXVII. **Unconjugated hyperbilirubinemia and liver histology in patients with non-alcoholic fatty liver disease**  
Kurt R., YILMAZ Y.  
CLINICAL BIOCHEMISTRY, vol.45, no.6, pp.515, 2012 (SCI-Expanded)
- CLXVIII. **Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology**  
Colak Y., Senates E., Ozturk O., YILMAZ Y., Zemheri E., Enc F. Y., Ulasoglu C., Aksaray S., Bozbeyoglu S. G., Kiziltas S., et al.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.24, no.3, pp.255-261, 2012 (SCI-Expanded)
- CLXIX. **Is M65 really better than M30 as a biomarker of hepatic fibrosis?**  
YILMAZ Y., Kurt R.  
HEPATOLOGY, vol.55, no.2, pp.654, 2012 (SCI-Expanded)
- CLXX. **NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Factors for Disease Progression?**  
YILMAZ Y.  
SEMINARS IN LIVER DISEASE, vol.32, no.1, pp.14-21, 2012 (SCI-Expanded)
- CLXXI. **The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy**  
Atasoy B. M., Yonal O., Demirel B., DANE F., YILMAZ Y., Kalayci C., Abacioglu U., Imeryuz N.  
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, vol.269, no.1, pp.275-282, 2012 (SCI-Expanded)
- CLXXII. **Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis**  
ÇOLAK Y., Senates E., Coskunpinar E., Oltulu Y. M., Zemheri E., Ozturk O., Doganay L., MESCİ B., YILMAZ Y., Enc F. Y.,



et al.

DISEASE MARKERS, vol.33, no.2, pp.77-83, 2012 (SCI-Expanded)

- CLXXIII. **Preliminary evidence of an association between the functional c-kit rs6554199 polymorphism and achalasia in a Turkish population**  
Alahdab Y., Eren F., Giral A., Gunduz F., Kedrah A. E., Atug O., Yilmaz Y., Kalayci O., Kalayci C.  
NEUROGASTROENTEROLOGY AND MOTILITY, vol.24, no.1, pp.27-30, 2012 (SCI-Expanded)
- CLXXIV. **Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration**  
YILMAZ Y., Kurt R., EREN F., Imeryuz N.  
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, vol.71, no.8, pp.631-636, 2011 (SCI-Expanded)
- CLXXV. **A Glance at the methods for detection of apoptosis qualitatively and quantitatively Apoptozun nitel ve nicel olarak tespitine yönelik metotlara kı{dotless}sa bir baki{dotless}ş**  
Ulukaya E., Acilan C., Ari F., Ikitimur E., Yilmaz Y.  
Turkish Journal of Biochemistry, vol.36, pp.261-269, 2011 (SCI-Expanded)
- CLXXVI. **Cytokeratins in hepatitis**  
YILMAZ Y.  
CLINICA CHIMICA ACTA, vol.412, pp.2031-2036, 2011 (SCI-Expanded)
- CLXXVII. **Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis**  
YILMAZ Y., EREN F., Ayyildiz T., Colak Y., Kurt R., Senates E., Tuncer I., Dolar E., Imeryuz N.  
CLINICA CHIMICA ACTA, vol.412, pp.2296-2299, 2011 (SCI-Expanded)
- CLXXVIII. **Plasma Fibrinogen-Like Protein 2 Levels in Patients with Non-Alcoholic Fatty Liver Disease**  
Colak Y., Senates E., Ozturk O., YILMAZ Y., Coskunpinar E., Kahraman O. T., Sahin O., Zemheri E., Enc F. Y., Ulasoglu C., et al.  
HEPATO-GASTROENTEROLOGY, vol.58, no.112, pp.2087-2090, 2011 (SCI-Expanded)
- CLXXIX. **Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity**  
Yilmaz Y., Yonal O., Eren F., Atug O., Hamzaoglu H. O.  
Journal of Crohn's and Colitis, vol.5, no.5, pp.402-406, 2011 (SCI-Expanded)
- CLXXX. **Association Between The Presence of Brown Adipose Tissue and Nonalcoholic Fatty Liver Disease in Adult Humans**  
Yilmaz Y., Ones T., Purnak T., Kurt R., Ozguven S., Atug O., Turoglu H., Imeryuz N.  
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)
- CLXXXI. **Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease**  
Senates E., YILMAZ Y., Colak Y., Ozturk O., Altunoz M. E., Kurt R., Ozkara S., Aksaray S., Tuncer I., Ovunc A. O. K.  
METABOLIC SYNDROME AND RELATED DISORDERS, vol.9, no.4, pp.287-290, 2011 (SCI-Expanded)
- CLXXXII. **Author's Reply; Noninvasive Tests of Fibrosis: To Get the Right Answers, We Need to Ask the Right Questions**  
YILMAZ Y., Kurt R.  
HEPATITIS MONTHLY, vol.11, no.8, pp.669-670, 2011 (SCI-Expanded)
- CLXXXIII. **Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans.**  
Yilmaz Y., Ones T., Purnak T., Ozguven S., Kurt R., Atug O., Turoglu H. T., Imeryuz N.  
Alimentary pharmacology & therapeutics, vol.34, no.3, pp.318-23, 2011 (SCI-Expanded)
- CLXXXIV. **Multimarker Strategies for Detecting NASH and NASH-Related Fibrosis: Promises and Caveats**  
YILMAZ Y., Kurt R., EREN F.  
OBESITY SURGERY, vol.21, no.8, pp.1316-1317, 2011 (SCI-Expanded)
- CLXXXV. **Apoptosis: why and how does it occur in biology?**  
ULUKAYA E., Acilan C., YILMAZ Y.  
CELL BIOCHEMISTRY AND FUNCTION, vol.29, no.6, pp.468-480, 2011 (SCI-Expanded)

- CLXXXVI. **Serum galectin-3 levels in patients with nonalcoholic fatty liver disease**  
YILMAZ Y., EREN F., Kurt R., Yonal O., Polat Z., Senates E., Bacha M., Imeryuz N.  
CLINICAL BIOCHEMISTRY, vol.44, no.12, pp.955-958, 2011 (SCI-Expanded)
- CLXXXVII. **Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease**  
YILMAZ Y., Kurt R., Gurdal A., ÖZEN ALAHDAB Y., Yonal O., Senates E., Polat N., EREN F., Imeryuz N., Oflaz H.  
ATHEROSCLEROSIS, vol.217, no.1, pp.125-129, 2011 (SCI-Expanded)
- :LXXXVIII. **Authors' Reply: Noninvasive liver fibrosis assessment; Why does the APRI not work for Hepatitis B?**  
YILMAZ Y., Yonal O., Kurt R.  
HEPATITIS MONTHLY, vol.11, no.7, pp.557, 2011 (SCI-Expanded)
- CLXXXIX. **Reply to Aydin et al: "To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?"**  
Yilmaz Y., Eren F.  
Metabolism: Clinical and Experimental, vol.60, 2011 (SCI-Expanded)
- CXC. **Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease**  
Aktas B., YILMAZ Y., EREN F., Yonal O., Kurt R., Alandab Y., ÇELİKEL Ç., Ozdogan O., Imeryuz N., Kalayci C., et al.  
METABOLISM-CLINICAL AND EXPERIMENTAL, vol.60, no.4, pp.544-549, 2011 (SCI-Expanded)
- CXCI. **Kefir Improves the Efficacy and Tolerability of Triple Therapy in Eradicating Helicobacter pylori**  
Bekar O., YILMAZ Y., Gulden M.  
JOURNAL OF MEDICINAL FOOD, vol.14, no.4, pp.344-347, 2011 (SCI-Expanded)
- CXCII. **Toward a Biochemical Diagnosis of NASH: Insights From Pathophysiology For Distinguishing Simple Steatosis From Steatohepatitis**  
Yilmaz Y., Ulukaya E.  
CURRENT MEDICINAL CHEMISTRY, vol.18, no.5, pp.725-732, 2011 (SCI-Expanded)
- CXCIII. **Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease**  
YILMAZ Y., Yonal O., Kurt R., Bayrak M., Aktas B., Ozdogan O.  
HEPATITIS MONTHLY, vol.11, no.2, pp.103-107, 2011 (SCI-Expanded)
- CXCIV. **Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease**  
Yilmaz Y., Yonal O., Kurt R., Alahdab Y., Ozdogan O., Celikel C. A., Ulukaya E., Imeryuz N., Kalayci C., Avsar E.  
Archives of Medical Research, vol.42, pp.38-43, 2011 (SCI-Expanded)
- CXCV. **Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy.**  
Ari E., Yilmaz Y., Kedrah A. E., Alahdab Y., Cakalagaoglu F., Arikan H., Koçak H., Macunluoglu B., Atakan A., Kahveci A., et al.  
American journal of nephrology, vol.33, no.3, pp.269-76, 2011 (SCI-Expanded)
- CXCVI. **Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease**  
Yilmaz Y., Eren F., Yonal O., Polat Z., Bacha M., Kurt R., Ozturk O., Avsar E.  
Disease Markers, vol.31, pp.205-210, 2011 (SCI-Expanded)
- CXCVII. **Serum zinc- $\alpha$ 2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease**  
Yilmaz Y., Yonal O., Eren F., Kurt R., Celikel C. A., Ozdogan O., Imeryuz N., Kalayci C., Avsar E.  
Clinical Chemistry and Laboratory Medicine, vol.49, pp.93-97, 2011 (SCI-Expanded)
- CXCVIII. **Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease**  
Yilmaz Y., Yonal O., Kurt R., Alahdab Y., Eren F., Ozdogan O., Celikel C. A., Imeryuz N., Kalayci C., Avsar E.  
Scandinavian Journal of Gastroenterology, vol.46, pp.91-97, 2011 (SCI-Expanded)
- CXCIX. **Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B**  
EREN F., YILMAZ Y., Kose S., Ozdemir F. T., Yonal O., Kurt R., Ozdogan O., Avsar E.  
CLINICA CHIMICA ACTA, vol.411, pp.2029-2032, 2010 (SCI-Expanded)

- CC. **Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease**  
Yılmaz Y., Yonal O., Kurt R., Oral A. Y., Eren F., Ozdogan O., Ari F., Çelikel Ç., Korkmaz S., Ulukaya E., et al.  
Scandinavian Journal of Clinical and Laboratory Investigation, vol.70, pp.541-546, 2010 (SCI-Expanded)
- CCI. **Liver Enzymes and Cardiovascular Outcomes a New Research Agenda**  
YILMAZ Y., Kuri R., Kalayci C.  
HEPATOLOGY, vol.52, no.6, pp.2242, 2010 (SCI-Expanded)
- CCII. **Serum fetuin A/alpha 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis**  
YILMAZ Y., Yonal O., Kurt R., ARI F., YILMAZTEPE ORAL A., ÇELİKEL Ç., KORKMAZ Ş., ULUKAYA E., Ozdogan O., Imeryuz N., et al.  
ANNALS OF CLINICAL BIOCHEMISTRY, vol.47, pp.549-553, 2010 (SCI-Expanded)
- CCIII. **Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments**  
YILMAZ Y., Kurt R., Kalayci C.  
BIOMARKERS IN MEDICINE, vol.4, no.5, pp.743-745, 2010 (SCI-Expanded)
- CCIV. **Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease**  
YILMAZ Y., Eren F., Yonal O., Kurt R., Aktas B., ÇELİKEL Ç., Ozdogan O., Imeryuz N., Kalayci C., Avsar E.  
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol.40, no.10, pp.887-892, 2010 (SCI-Expanded)
- CCV. **Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis**  
YILMAZ Y., Alanhdab Y., Yonal O., Kurt R., Kedrah A. E., ÇELİKEL Ç., Ozdogan O., DUMAN D., Imeryuz N., Avsar E., et al.  
METABOLISM-CLINICAL AND EXPERIMENTAL, vol.59, no.9, pp.1327-1330, 2010 (SCI-Expanded)
- CCVI. **Microalbuminuria and nonalcoholic fatty liver disease**  
Yılmaz Y., Alahdab Y. O., Yonal O., Imeryuz N., Kalayci C.  
Metabolism: Clinical and Experimental, vol.59, 2010 (SCI-Expanded)
- CCVII. **The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts**  
Yılmaz Y.  
JOURNAL OF GASTROENTEROLOGY, vol.45, no.7, pp.782-783, 2010 (SCI-Expanded)
- CCVIII. **Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis**  
YILMAZ Y., Kurt R., Yonal O., Polat N., ÇELİKEL Ç., Gurdal A., Oflaz H., Ozdogan O., Imeryuz N., Kalayci C., et al.  
ATHEROSCLEROSIS, vol.211, no.1, pp.182-186, 2010 (SCI-Expanded)
- CCIX. **Folic Acid and Vitamin B12 Supplementation Improves Coronary Flow Reserve in Elderly Subjects with Vitamin B12 Deficiency**  
Kurt R., YILMAZ Y., Ermis F., Besisik S. K., Polat N., Elitok A., Oflaz H., Karan M. A.  
ARCHIVES OF MEDICAL RESEARCH, vol.41, no.5, pp.369-372, 2010 (SCI-Expanded)
- CCX. **Cigarette Smoking Is Not Associated with Specific Histological Features or Severity of Nonalcoholic Fatty Liver Disease**  
YILMAZ Y., Yonai O., Kurt R., Avsar E.  
HEPATOLOGY, vol.52, no.1, pp.391, 2010 (SCI-Expanded)
- CCXI. **C-KIT Gene Polymorphism in Achalasia**  
Alahdab Y. O., EREN F., Gunduz F., Kedrah A. E., YILMAZ Y., Atug O., Imeryuz N., Giral A., Avsar E., Kalayci C.  
GASTROENTEROLOGY, vol.138, no.5, 2010 (SCI-Expanded)
- CCXII. **Microalbuminuria in Nondiabetic Patients With Nonalcoholic Fatty Liver Disease: Association With Liver Fibrosis**  
YILMAZ Y., Alahdab Y. O., Yonal O., Kurt R., Kedrah A. E., Celikel C. A., Duman D., Ozdogan O., Imeryuz N., Avsar E., et al.  
GASTROENTEROLOGY, vol.138, no.5, 2010 (SCI-Expanded)
- CCXIII. **The Impact of Prophylactic Percutaneous Endoscopic Gastrostomy to Nutritional Status and Quality of Life in Locally Advanced Head and Neck Cancer Patients Receiving Chemoradiotherapy**

- Yonal O, Atasoy B. M., Demirel B., YILMAZ Y., Dane F., ABACIOGLU M. U., Kalayci C., Imeryuz N.  
GASTROENTEROLOGY, vol.138, no.5, 2010 (SCI-Expanded)
- CCXIV. **Molecular Signatures of Nonalcoholic Fatty Liver Disease: The Present and Future**  
YILMAZ Y., ULUKAYA E.  
HEPATOLOGY, vol.51, no.5, pp.1866, 2010 (SCI-Expanded)
- CCXV. **Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis**  
Olmez O. F., Gurel S., YILMAZ Y.  
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.22, no.4, pp.461-465, 2010 (SCI-Expanded)
- CCXVI. **M30 levels and nonalcoholic steatohepatitis in polycystic ovary syndrome**  
Yilmaz Y., Kurt R.  
Journal Of Clinical Endocrinology, vol.0, no.0, 2010 (SCI-Expanded)
- CCXVII. **Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients**  
Gul O. O., Tuncel E., YILMAZ Y., ULUKAYA E., Gul C. B., Kiyici S., YILMAZTEPE ORAL A., Guclu M., ERSOY C., Imamoglu S.  
METABOLISM-CLINICAL AND EXPERIMENTAL, vol.59, no.1, pp.64-69, 2010 (SCI-Expanded)
- CCXVIII. **Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: Relationship with the severity of coronary artery disease**  
Senturk T., Aydinlar A., Yilmaz Y., Yilmaztepe Oral A., Ozdabakoglu O., Ulukaya E.  
Coronary Artery Disease, vol.20, pp.494-498, 2009 (SCI-Expanded)
- CCXIX. **Systematic review: Caspase-cleaved fragments of cytokeratin 18 - The promises and challenges of a biomarker for chronic liver disease**  
Yilmaz Y.  
Alimentary Pharmacology and Therapeutics, vol.30, pp.1103-1109, 2009 (SCI-Expanded)
- CCXX. **Familial Mediterranean Fever coexisting with celiac disease: Is there a link with long-term colchicine treatment?**  
Yilmaz Y., Baran B., Seniz N. B., Dolar E.  
Journal of Gastrointestinal and Liver Diseases, vol.18, pp.119-120, 2009 (SCI-Expanded)
- CCXXI. **Metformin, hepatitis C, and insulin resistance: Sufficient evidence?**  
Yilmaz Y., Yonal O., Imeryuz N.  
Hepatology, vol.50, pp.2054-2055, 2009 (SCI-Expanded)
- CCXXII. **Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients**  
Arabul M., Gullulu M., Yilmaz Y., Eren M. A., Baran B., Gul C. B., Kocamaz G., Dilek K.  
Medical Science Monitor, vol.15, 2009 (SCI-Expanded)
- CCXXIII. **Serum concentrations of human angiotensin-like protein 3 in patients with nonalcoholic fatty liver disease: Association with insulin resistance**  
Yilmaz Y., Ulukaya E., Atuğ Ö., Dolar E.  
European Journal of Gastroenterology and Hepatology, vol.21, pp.1247-1251, 2009 (SCI-Expanded)
- CCXXIV. **Non-alcoholic fatty liver disease and microalbuminuria in non-diabetic patients: Role of insulin resistance**  
Yilmaz Y., Alahdab Y., Özdoğan O. C., Dolar E.  
Internal Medicine Journal, vol.39, pp.709-710, 2009 (SCI-Expanded)
- CCXXV. **Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count.**  
Ari E., YILMAZ Y., Gul A., ÖZEN ALAHDAB Y., Kedrah A. E., Macunluoglu B., Aydin A., Arikan H., Ozener C.  
American journal of reproductive immunology (New York, N.Y. : 1989), vol.62, no.4, pp.238-42, 2009 (SCI-Expanded)
- CCXXVI. **Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis**  
YILMAZ Y., Kedrah A. E., Ozdogan O.  
WORLD JOURNAL OF GASTROENTEROLOGY, vol.15, no.35, pp.4387-4391, 2009 (SCI-Expanded)
- CCXXVII. **Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or**

**decorations?**

YILMAZ Y., Dolar E.

WORLD JOURNAL OF GASTROENTEROLOGY, vol.15, no.34, pp.4346-4347, 2009 (SCI-Expanded)

- CCXXVIII. **Commentary on "Cytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Disease"**

YILMAZ Y., Dolar E., ULUKAYA E.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, vol.49, no.3, pp.371, 2009 (SCI-Expanded)

- CCXXIX. **"Defragmenting" the Noninvasive Diagnosis of Nonalcoholic Steatohepatitis: Hopes from Cytokeratin-18**

Yilmaz Y.

HEPATOLOGY, vol.50, no.3, pp.990-991, 2009 (SCI-Expanded)

- CCXXX. **The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond**

Yilmaz Y., Ulukaya E., Dolar E.

Hepatology, vol.49, pp.1056-1057, 2009 (SCI-Expanded)

- CCXXXI. **Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels**

Yilmaz Y., Ulukaya E., Dolar E.

Hepatology, vol.49, pp.697, 2009 (SCI-Expanded)

- CCXXXII. **Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease**

YILMAZ Y., ULUKAYA E., Gul O. O., Arabul M., Gul C. B., ATUĞ Ö., YILMAZTEPE ORAL A., Aker S., Dolar E.

CLINICAL BIOCHEMISTRY, vol.42, no.9, pp.802-807, 2009 (SCI-Expanded)

- CCXXXIII. **Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C**

Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., Yerci O., Oral A. Y., Gul C. B., Gurel S., et al.

Medical Science Monitor, vol.15, 2009 (SCI-Expanded)

- CCXXXIV. **Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C**

ATUĞ Ö., Akin H., YILMAZ Y., Sari M., Tozun N.

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, vol.18, no.2, pp.256, 2009 (SCI-Expanded)

- CCXXXV. **Coronary artery anomalies in patients with syndrome X**

Akgüllü Ç., Yilmaz Y., Yücel E., Kaderli A. A., Kumbay E., Aydinlar A.

Anadolu Kardiyoloji Dergisi, vol.9, pp.69, 2009 (SCI-Expanded)

- CCXXXVI. **Serum Levels of Adipokines in Patients with Chronic HCV Infection: Relationship with Steatosis and Fibrosis**

Tiftkci A., ATUĞ Ö., YILMAZ Y., EREN F., Ozdemir F. T., Yapali S., Ozdogan O., ÇELİKEL Ç., Imeryuz N., Tozun N.

ARCHIVES OF MEDICAL RESEARCH, vol.40, no.4, pp.294-298, 2009 (SCI-Expanded)

- CCXXXVII. **Dipeptidyl peptidase IV inhibitors: Therapeutic potential in nonalcoholic fatty liver disease**

YILMAZ Y., ATUĞ Ö., Yonal O., DUMAN D., Ozdogan O., Imeryuz N., Kalayci C.

MEDICAL SCIENCE MONITOR, vol.15, no.4, 2009 (SCI-Expanded)

- CCXXXVIII. **Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: Relation to disease severity**

Keskin M., Dolar E., Dirican M., Kiyici M., Yilmaz Y., Gurel S., Nak S., Erdinc S., Gulden M.

Internal Medicine Journal, vol.39, pp.243-248, 2009 (SCI-Expanded)

- CCXXXIX. **Liver Disease as a Risk Factor for Cognitive Decline and Dementia: an Under-Recognized Issue**

YILMAZ Y., Ozdogan O.

HEPATOLOGY, vol.49, no.2, pp.698, 2009 (SCI-Expanded)

- CCXL. **Small arterial elasticity predicts the extent of coronary artery disease: Relationship with serum uric acid**

Fazlıoğlu M., Şentürk T., Kumbay E., Kaderli A. A., Yilmaz Y., Özdemir B., Baran I., Aydinlar A.

Atherosclerosis, vol.202, pp.200-204, 2009 (SCI-Expanded)

- CCXLI. **Acute arsenic self-poisoning for suicidal purpose in a dentist: A case report**  
Yilmaz Y., Armagan E., Olmez O., Esen M., Alkis N., Dolar E.  
Human and Experimental Toxicology, vol.28, pp.63-65, 2009 (SCI-Expanded)
- CCXLII. **Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry**  
ULUKAYA E., YILMAZ Y., Moshkovskii S., Karpova M., Pyatnitskiy M., ATUĞ Ö., Dolar E.  
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.44, no.12, pp.1471-1476, 2009 (SCI-Expanded)
- CCXLIII. **Predictive value of the modified early warning score in a turkish emergency department**  
Armagan E., Yilmaz Y., Olmez O. F., Simsek G., Gul C. B.  
European Journal of Emergency Medicine, vol.15, pp.338-340, 2008 (SCI-Expanded)
- CCXLIV. **Concomitant colitis in a patient with Behcet's disease**  
Yilmaz Y., Dolar E.  
Journal of Gastrointestinal and Liver Diseases, vol.17, no.4, pp.481-483, 2008 (SCI-Expanded)
- CCXLV. **A "biomarker biopsy" for the diagnosis of NASH: Promises from CK-18 fragments**  
Yilmaz Y., Ulukaya E., Dolar E.  
Obesity Surgery, vol.18, pp.1507-1508, 2008 (SCI-Expanded)
- CCXLVI. **Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease**  
Arabul M., Gullulu M., Yilmaz Y., Akdag I., Kahvecioglu S., Ali Eren M., Dilek K.  
Clinical Biochemistry, vol.41, pp.1055-1058, 2008 (SCI-Expanded)
- CCXLVII. **The Pro12Ala polymorphism of peroxisome proliferator-activated receptor- $\gamma$ 2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease**  
Catalano M., Cortelazzo A., Santi R., Contino L., Demicheli M., Yilmaz Y., Zorzetto M., Campo I., Lanati N., Emanuele E.  
Clinical Biochemistry, vol.41, pp.981-985, 2008 (SCI-Expanded)
- CCXLVIII. **Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease**  
Akgullu C., Ozdemir B., Yilmaz Y., Kazazoglu A. R., Aydinlar A.  
Acta Cardiologica, vol.63, no.4, pp.467-471, 2008 (SCI-Expanded)
- CCXLIX. **Helicobacter pylori: A role in schizoprenia?**  
Yilmaz Y., Gul C. B., Arabul M., Eren M. A.  
Medical Science Monitor, vol.14, 2008 (SCI-Expanded)
- CCL. **Apical ballooning syndrome: A metabolic form of cardiomyopathy?**  
Yilmaz Y.  
Medical Science Monitor, vol.14, 2008 (SCI-Expanded)
- CCLI. **Urinary IL-18: A marker of contrast-induced nephropathy following percutaneous coronary intervention?**  
Bulent Gul C., Gullulu M., Oral B., Aydinlar A., Oz O., Budak F., Yilmaz Y., Yurtkuran M.  
Clinical Biochemistry, vol.41, pp.544-547, 2008 (SCI-Expanded)
- CCLII. **The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease**  
Falcone C., Geroldi D., Buzzi M. P., Emanuele E., Yilmaz Y., Fontana J. M., Vignali L., Boiocchi C., Sbarsi I., Cuccia M.  
Archives of Medical Research, vol.39, pp.320-325, 2008 (SCI-Expanded)
- CCLIII. **Acute myocardial infarction, ischemic cerebrovascular disease and variceal bleeding due to portal vein thrombosis in a patient with hereditary thrombophilia**  
Baran B., Yilmaz Y., Algin O., Keskin M., Kiyici M., Kocamaz G., Dolar E.  
Blood Coagulation and Fibrinolysis, vol.19, pp.243-246, 2008 (SCI-Expanded)
- CCLIV. **Psychopathology in the context of obesity: The adiponectin hypothesis**  
Yilmaz Y.  
Medical Hypotheses, vol.70, pp.902-903, 2008 (SCI-Expanded)
- CCLV. **Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: A 5-year prospective study**  
Akdag I., Yilmaz Y., Kahvecioglu S., Bolca N., Ercan I., Ersoy A., Gullulu M.

- Nephron - Clinical Practice, vol.108, 2008 (SCI-Expanded)
- CCLVI. **The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease**  
Catalano M., Cortelazzo A., Yilmaz Y., Perilli E., Carzaniga G., Emanuele E.  
Clinica Chimica Acta, vol.387, pp.109-112, 2008 (SCI-Expanded)
- CCLVII. **Evaluation of leukocyte esterase and nitrite strip tests to detect spontaneous bacterial peritonitis in cirrhotic patients**  
Torun S., Dolar E., Yilmaz Y., Keskin M., Kiyici M., Sinirtas M., Sarandol E., Gurel S., Nak S. G., Gulden M.  
World Journal of Gastroenterology, vol.13, pp.6027-6030, 2007 (SCI-Expanded)
- CCLVIII. **Clinical significance of activity of ALT enzyme in patients with hepatitis C virus**  
Akkaya O., Kiyici M., Yilmaz Y., Ulukaya E., Yerci O.  
World Journal of Gastroenterology, vol.13, pp.5481-5485, 2007 (SCI-Expanded)
- CCLIX. **Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis**  
Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., Aker S., Yilmaztepe A., Gurel S., Gulden M., et al.  
World Journal of Gastroenterology, vol.13, pp.837-844, 2007 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Optimal testing strategies for incidental anti-mitochondrial M2 antibody-positive patients**  
Ergenc I., Gozaydinoglu B., Keklikkiran C., YILMAZ Y.  
Hepatology Forum, vol.5, no.3, pp.165-166, 2024 (Scopus)
- II. **Predicting fibrosis progression in non-alcoholic fatty liver disease patients using the FAST Score: A paired biopsy study**  
Sariyar N., KANI H. T., ÇELİKEL Ç., YILMAZ Y.  
Hepatology Forum, vol.5, no.1, pp.33-36, 2024 (Scopus)
- III. **Addressing the looming epidemic of metabolic dysfunction-associated steatotic liver disease in Pakistan: A call for action**  
Kamani L., Rahat A., YILMAZ Y.  
Hepatology Forum, vol.5, no.1, pp.1-2, 2024 (Scopus)
- IV. **Vibration-controlled transient elastography for non-invasive screening of liver fibrosis and steatosis in Turkish patients with psoriasis: A cross-sectional study**  
Aksoy A. N., Hanci B., Baskent M. F., Umutlu E. G., Kumas E. N., Emanet S. U., Yalcin M. O., Duzyol Z., Teker A. G., YILMAZ Y.  
Hepatology Forum, vol.5, no.1, pp.29-32, 2024 (Scopus)
- V. **Prevalence, determinants, and fibrosis risk stratification of metabolic-associated fatty liver disease in a Turkish primary care setting: A retrospective study.**  
Arslan A. Y., Celik S., Amin F., Caylak I., Kesapli I., Kilic I. B., Karakullukcu S., Ardic C., Yilmaz Y.  
Hepatology forum, vol.5, no.2, pp.63-67, 2023 (ESCI)
- VI. **The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients**  
ERGENÇ İ., Gozaydinoglu B., KEKLİKKİRAN C., YILMAZ Y.  
Hepatology forum, vol.4, no.2, pp.69-73, 2023 (Peer-Reviewed Journal)
- VII. **TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease**  
Yilmaz Y., Zeybel M., Adali G., Coşar A., Serteser E., Sümer H., Bahcecioglu I. H., Şahin M., Kaya C. T., Ergün İ., et al.  
Hepatology forum, vol.4, no.1, pp.1-32, 2023 (Peer-Reviewed Journal)
- VIII. **The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease**  
YILMAZ Y., Kaya E.  
HEPATOLOGY FORUM, vol.4, no.2, 2023 (ESCI)

- IX. Chronotype preference, sleep quality, and night-eating behaviors in patients with metabolic dysfunction-associated steatotic liver disease: Assessing the relationship with disease severity and fibrosis**  
Sakallı Kani A., Ozercan A., Kani H. T., Eren F., Sayar K., Yılmaz Y.  
Hepatology Forum, vol.4, no.3, pp.123-128, 2023 (Scopus)
- X. Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease**  
Eris T., Hassan M., Hikal Y., Sawah E., Daneshgar F., Teker A. G., Ozel F., Lüleci N. E., Kaya E., Yılmaz Y.  
HEPATOLOGY FORUM, vol.4, no.1, pp.7-13, 2023 (ESCI)
- XI. Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan**  
Yesil E. E., Yılmaz Y., Yesil A., Mese M., Kaya E., Bakir E. A.  
HEPATOLOGY FORUM, vol.4, no.1, pp.14-18, 2023 (ESCI)
- XII. The heated debate over NAFLD renaming: An ongoing saga**  
YILMAZ Y.  
Hepatology Forum, vol.4, no.3, pp.89-91, 2023 (Scopus)
- XIII. Insidious danger for young adults: Metabolic (dysfunction)associated fatty liver disease**  
Kaya E., YILMAZ Y.  
HEPATOLOGY FORUM, vol.3, no.2, pp.39-40, 2022 (ESCI)
- XIV. Prevention of hepatocellular carcinoma and surveillance of high risk patients**  
Kaya E., Mazzolini G. D., YILMAZ Y., CANBAY A.  
Hepatology Forum, vol.3, pp.33-38, 2022 (ESCI)
- XV. Demographic Characteristics and Transmission Risk Factors of Patients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial**  
TABAK F., ŞİRİN G., DEMİR M., ALADAĞ M., SÜMER Ş., KURTARAN B., TOSUN S., YAMAZHAN T., BOZKURT İ., GÜRBÜZ Y., et al.  
Viral Hepatitis Journal, vol.27, no.3, pp.109-117, 2021 (ESCI)
- XVI. The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study**  
YILMAZ Y., YILMAZ N., ATEŞ F., KARAKAYA F., GÖKCAN H., KAYA E., ADALI G., ÇALIŞKAN KARTAL A., ŞEN İ., AHISHALI E., et al.  
Hepatology Forum, vol.2, no.2, pp.37-42, 2021 (ESCI)
- XVII. Comparison of aerobic and combined aerobic and whole-body vibration training effects on physical fitness in non-alcoholic fatty liver patients**  
Saldıran T. C., Mutluay F. K., Yagci İ., Yılmaz Y.  
COMPARATIVE EXERCISE PHYSIOLOGY, vol.17, no.4, pp.393-401, 2021 (ESCI)
- XVIII. High incidence of hepatitis B core antibody positivity in metabolic-associated fatty liver disease-related cirrhosis**  
ERGENÇ İ., GÖKÇEN P., ADALI G., Kani H. T., Demirtaş C. Ö., Gündüz F., Çelikel Ç. A., YILMAZ Y.  
Hepatology Forum, vol.1, no.2, pp.20-25, 2021 (ESCI)
- XIX. The clinical and histological characteristics of patients with biopsy-proven non-alcoholic fatty liver disease in the absence of insulin resistance**  
DEMİRTAŞ C. Ö., SAPMAZ A., GÜREL B. A., KIZMAZ H., ULU T., KARAKETİR Ş. G., YILMAZ Y.  
Hepatology Forum, vol.1, no.3, pp.101-108, 2020 (Peer-Reviewed Journal)
- XX. Metabolic-associated Fatty Liver Disease: Time to integrate ground-breaking new terminology to our clinical practice?**  
DEMİRTAŞ C. Ö., YILMAZ Y.  
Hepatology Forum, vol.1, no.3, pp.79-81, 2020 (Peer-Reviewed Journal)
- XXI. Regular coffee intake improves liver enzyme levels and liver histology in patients with chronic alcohol consumption, non-alcoholic fatty liver and non-alcoholic steatohepatitis: Report of 259 cases**  
DEĞERTEKİN M. B., TÖZÜN A. N., Söylemez A. G., Gurtay E., Bozkurt U., YILMAZ Y., YAPALI S., VARDARELİ N. E.,



ÜNAL H. Ü., Çolakoğlu B., et al.

Hepatology Forum, vol.1, no.3, pp.88-96, 2020 (Peer-Reviewed Journal)

**XXII. The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases**

Kaya E., Bakır A., Eren F., Yılmaz Y.

Hepatology Forum, vol.1, no.1, pp.8-13, 2020 (Peer-Reviewed Journal)

**XXIII. The comparison of resting metabolic rate between biopsy-proven non-alcoholic steatohepatitis and non-alcoholic fatty liver patients**

KENGER E. B., GÜVELİ H., Ergun C., Kaya E., YILMAZ Y.

Hepatology Forum, vol.1, no.1, pp.14-19, 2020 (Peer-Reviewed Journal)

**XXIV. Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter**

Kani H. T., Deliktas I., YILMAZ Y.

MARMARA MEDICAL JOURNAL, vol.32, no.2, pp.68-70, 2019 (ESCI)

**XXV. Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?**

Yılmaz Y.

World Journal of Hepatology, vol.4, pp.332-334, 2012 (Scopus)

**XXVI. A Glance at the methods for detection of apoptosis qualitatively and quantitatively**

Ulukaya E., Açılan C., Arı F., Elif İlkay İ., Yılmaz Y.

A Glance at the methods for detection of apoptosis qualitatively and quantitatively, vol.36, pp.261-269, 2011 (Peer-Reviewed Journal)

**XXVII. Liver function tests: Association with cardiovascular outcomes**

Yılmaz Y.

World Journal of Hepatology, vol.2, pp.143-145, 2010 (Scopus)

## Books & Book Chapters

**I. Non-invasive, serum-based evaluation of liver fibrosis in metabolic (dysfunction)-associated fatty liver disease**

KAYA E., YILMAZ Y.

in: Metabolic Steatotic Liver Disease Current Knowledge, Therapeutic Treatments, and Future Directions, HENRY LINDA, NGUYEN MINDIE, Editor, ELSEVIER, STANDFORD, pp.137-150, 2024

**II. Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease: An Incomplete Jigsaw Puzzle**

Pan Q., Fan J., Yılmaz Y.

in: Clinics in Liver Disease: Update on Non-Alcoholic Steatohepatitis, Norman Gitlin, Zobair M. Younossi, Editor, Elsevier Science, Oxford/Amsterdam, Pennsylvania, pp.317-332, 2023

**III. Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease: An Incomplete Jigsaw Puzzle**

Pan Q., Fan J., YILMAZ Y.

in: Update on Non-Alcoholic Steatohepatitis, Zobair M. Younossi, Editor, Elsevier, pp.317-332, 2023

**IV. Covid-19 ve Karaciğer Yağlanması İlişkisi Nasıl Gelişmektedir?**

Demirtaş C. Ö., YILMAZ Y.

in: Türkiye Klinikleri Gastroenteroloji ve Covid-19, Ahmet Uygun, Editor, Türkiye Klinikleri, Ankara, pp.39-44, 2021

**V. Non-alcoholic Fatty Liver Disease: A Global Public Health Issue**

Kaya E., Yılmaz Y.

in: Obesity and Diabetes, Joel Faintuch, Salomão Faintuc, Editor, Springer-Verlag, Zürich, pp.1-987, 2020

**VI. Alkol Dışı Yağlı Karaciğer Hastalığı**

KEFELİ A., YILMAZ Y.

in: Hepatobiliyer Sistem ve Pankreas Hastalıkları, Kefeli, Ayşe, Editor, Akademisyen Yayınevi, Ankara, pp.193-209, 2020

**VII. Non-alcoholic Fatty Liver Disease: A Global Public Health Issue**

KAYA E., YILMAZ Y.

in: Obesity and Diabetes, Faintuch, Joel, Faintuch, Salomão, Editor, Springer, pp.321-333, 2020

VIII. **Epidemiology of Nonalcoholic Fatty Liver Disease in Turkey and in the World**

Kaya E., Yılmaz Y.

in: Türkiye Klinikleri Gastroenterohepatoloji-Özel Konular: Nonalkolik Yağlı Karaciğer Hastalığı, Abdullah Sonsuz, Editor, Türkiye Klinikleri (Ortadoğu Reklam Tanıtım Yayıncılık), Ankara, pp.1-7, 2019

IX. **Türkiye’de ve Dünyada Nonalkolik Yağlı Karaciğer Hastalığı Epidemiyolojisi**

Kaya E., YILMAZ Y.

in: Türkiye Klinikleri Gastroenterohepatoloji-Özel Konular Nonalkolik Yağlı Karaciğer Hastalığı, Abdullah Sonsuz, Editor, Türkiye Klinikleri (Ortadoğu Reklam Tanıtım Yayıncılık), Ankara, pp.1-7, 2019

X. **Is NAFLD different in absence of metabolic syndrome?**

Yılmaz Y.

in: Clinical Dilemmas in Non Alcoholic Fatty Liver Disease, Roger Williams, Simon D. Taylor-Robinson, Editor, Wiley-VCH Verlag Weinheim GmbH , London, pp.50-57, 2016

XI. **Is NAFLD different in absence of metabolic syndrome?**

YILMAZ Y.

in: Clinical Dilemmas in Non Alcoholic Fatty Liver Disease, Roger Williams, Simon D. Taylor-Robinson, Editor, Wiley-Blackwell, Chichester, pp.50-57, 2016

XII. **Obesity-Associated Nonalcoholic Fatty Liver Disease**

Yılmaz Y., Younossi Z.

in: OBESITY A Multidisciplinary Approach, Joel J. Heidelbaugh, Editor, Elsevier Science, Oxford/Amsterdam , Pennsylvania, pp.93-107, 2015

XIII. **Obesity-Associated Nonalcoholic Fatty Liver Disease**

YILMAZ Y., YOUNOSSI Z. M.

in: OBESITY A Multidisciplinary Approach, Joel J. Heidelbaugh, Editor, ELSEVIER, Philadelphia, pp.93-107, 2015

## **Refereed Congress / Symposium Publications in Proceedings**

I. **Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Experience Significant Disease Burden and Stigma**

Younossi Z., YILMAZ Y., Fan J., Zheng M., ALSWAT K. A., ALQAHTANI S., EL-KASSAS M., CASTERA L., FUNUYET-SALAS J., ROMERO-GOMEZ M., et al.

American Diabetes Association (ADA) 2024 Annual Congress, United States Of America, 15 June 2024, vol.73, pp.1414

II. **Clinical and biochemical characteristics of a Danish and Turkish cohort of incident and prevalent patients with primary biliary cholangitis**

Eruzun H., Bossen L., TURAN D., Ergenç İ., HARPUT Z. N., GÜNEŞ AYDEMİR N., AKDOĞAN KAYHAN M., Yapıcı H. B., Holland-Fischer P., Bach Hansen J., et al.

EASL Congress 2024, Milan, Italy, 05 June 2024, vol.80, pp.723

III. **Spleen stiffness measurement improves non-invasive prediction of clinically significant portal hypertension in primary biliary cholangitis**

Francesca Manfredi G., Ergenç İ., Cittone M., Degaspero E., Neglia M. C., Bertetto R., Benedittis C. D., Yapıcı H. B., Pirisi M., Calvaruso V., et al.

EASL Congress 2024, Milan, Italy, 05 June 2024, vol.80, pp.329

IV. **Fatigue is an Important Driver of Work Productivity Loss and Impairment of Patient-Reported Outcomes (PROs) among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)**

Younossi Z., YILMAZ Y., Yu M., Isakov V., Fernández M. I. C., Wong V. W., Eguchi Y., Romero-Gómez M., Méndez-Sánchez N., Duseja A. K., et al.

EASL Congress 2024, Milan, Italy, 05 June 2024, vol.80, pp.643

- V. **Prevalence and predictors of clinically significant pruritus in patients with non-alcoholic fatty liver disease (NAFLD): data from the global NASH registry™ (GNR™)**  
 Younossi Z. M., YILMAZ Y.  
 Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2023, Boston, United States Of America, 10 November 2023, vol.78, pp.863
- VI. **THE GLOBAL SURVEY OF DISEASE BURDEN AND STIGMA AMONG PATIENTS WITH NAFLD AND THEIR HEALTHCARE PROVIDERS**  
 Younossi Z. M., YILMAZ Y.  
 Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2023, Boston, United States Of America, 10 November 2023, vol.78, pp.1050-1056
- VII. **A GLOBAL SURVEY OF PHYSICIAN KNOWLEDGE ABOUT MANAGEMENT OF CHRONIC HEPATITIS C**  
 Younossi Z. M., YILMAZ Y.  
 American Association for the Study of Liver Diseases (AASLD) Meeting 2023, Boston, United States Of America, 10 November 2023, vol.78, pp.671
- VIII. **Stigma in NAFLD and NASH: a global survey of patients and providers**  
 Younossi Z. M., YILMAZ Y.  
 International Liver Congress (EASL) 2023, Viyana, Austria, 01 June 2023, vol.78, pp.627-628
- IX. **STIGMA IS A PREDICTOR OF IMPAIRMENT OF HEALTH RELATED QUALITY OF LIFE AMONG PATIENTS WITH NAFLD**  
 Younossi Z. M., YILMAZ Y.  
 Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2023, Boston, United States Of America, 10 November 2023, vol.78, pp.1768-1774
- X. **Transient elastography measurements of spleen stiffness are associated with treatment response to ursodeoxycholic acid in primary biliary cholangitis**  
 ERGENÇ İ., YAPICI H., KEKLIKIRAN Ç., YILMAZ Y.  
 International Liver Congress (EASL) 2023, Austria, 21 - 24 June 2023, vol.78, pp.389-390
- XI. **NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH SIGNIFICANT IMPAIRMENT OF WORK PRODUCTIVITY: DATA FROM THE GLOBAL NASH REGISTRY™**  
 Younossi Z., YILMAZ Y., Yu M., Wong V., Fernandez M., Isakov V., Duseja A., Mendez-Sanchez N., Eguchi Y., Bugianesi E., et al.  
 vol.77
- XII. **Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease and type 2 diabetes**  
 Pennisi G., Enea M., Falco V., Aithal G., Palaniyappan N., YILMAZ Y., Boursier J., Cassinotto C., Ledinghen V. d., Chan W., et al.  
 55th A.I.S.F. - Italian Association for the Study of the Liver - Annual Meeting 2023, Milan, Italy, 14 March 2023, vol.55, pp.12-15
- XIII. **CLINICAL AND PATIENT-REPORTED OUTCOME (PRO) PROFILE OF PATIENTS WITH HEPATITIS B VIRAL (HBV) INFECTION FROM THE GLOBAL LIVER REGISTRY (TM) (GLR (TM))**  
 Younossi Z. M., YILMAZ Y.  
 Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2022, Washington, Kiribati, 04 November 2022, vol.76, pp.287-288
- XIV. **DEPRESSION AND EMOTIONAL DISTRESS IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY**  
 Younossi Z. M., Stepanova M., Fernandez M. I. C., YILMAZ Y., Yu M., El Kassas M., Esmat G., Isakov V. A., Wong V. W., Eguchi Y., et al.  
 Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2022, Washington, Kiribati, 04 October 2022, vol.76, pp.1049-1051
- XV. **REAL-WORLD EVIDENCE ON NON-INVASIVE TESTS AND ASSOCIATED CUT-OFFS USED TO ASSESS FIBROSIS IN ROUTINE CLINICAL PRACTICE**  
 Lazarus J. V., YILMAZ Y.

Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2022, Washington, Kiribati, 04 November 2022, vol.76, pp.818-820

- XVI. **Lean non-alcoholic fatty liver disease patients from the global NASH registry**  
YILMAZ Y.  
EASL, Londrina, Brazil, 22 June 2022
- XVII. **Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease**  
YILMAZ Y.  
EASL, Londrina, Brazil, 22 June 2022
- XVIII. **Multimodality assessment of hepatic fibrosis: ranked paired reading and artificial intelligence identifies fibrosis improvement with aramchol missed by conventional staging**  
YILMAZ Y.  
EASL, Londrina, Brazil, 22 June 2022
- XIX. **ANALYSIS OF THE EFFICACY OF A HIGHER DAILY ARAMCHOL DOSE ON FIBROSIS IMPROVEMENT IN THE ARMOR STUDY OPEN LABEL PART**  
Gorfine T., Ratziu V., YILMAZ Y., Friedman S. L., Hayardeny L., Kadosh S., Sanyal A. J.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 12 November 2021
- XX. **Development and validation of Agile 4 and Agile 3+: Novel FibroScan based scores for the diagnosis of cirrhosis and advanced fibrosis in patients with non-alcoholic fatty liver disease**  
YILMAZ Y.  
French Hepatology congress (AFEF) 29 Eylül 2021-02 Ekim 2021, Biarritz, France, 07 July 2021
- XXI. **The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry**  
YOUNOSSI Z. M., YILMAZ Y., El Kassas M., Duseja A. K., Saeed H., Gammal E., Mendez-Sanchez N., CHAN W. K., Ashwani S., Brian L., et al.  
International Liver Congress (EASL), Roma, Italy, 23 June 2021, vol.75, pp.655
- XXII. **The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge?**  
Lazarus J., Mark H., Palayew A., Patrizia C., Colombo M., Ekstedt M., Esmat G., George J., Reggiani G. M., Novak K., et al.  
International Liver Congress, ELECTR NETWORK, 23 - 26 June 2021, vol.75
- XXIII. **Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosis**  
YILMAZ Y.  
International Liver Congress (EASL), Roma, Italy, 23 June 2021, vol.75, pp.259-260
- XXIV. **Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease**  
YOUNOSSI Z. M., Harrison S. A., Newsome P. N., CHAN W. K., YILMAZ Y., Ledinghen V. d., Costentin C., Zheng M., Wong V. W., Elkhatab M., et al.  
International Liver Congress (EASL), Roma, Italy, 23 - 26 June 2021, vol.75, pp.257
- XXV. **A GLOBAL SURVEY OF PHYSICIANS KNOWLEDGE ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)**  
YILMAZ Y.  
Digestive Disease Week, United States Of America, 21 May 2021, vol.160, pp.830
- XXVI. **CLINICAL PRESENTATION OF LEAN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY**  
YILMAZ Y.  
Digestive Disease Week, United States Of America, 21 May 2021, vol.160, pp.771-772
- XXVII. **CLINICAL PRESENTATION AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS: DATA FROM THE GLOBAL LIVER REGISTRY (TM)**

- YILMAZ Y.  
Digestive Disease Week, United States Of America, 21 May 2021, vol.160, pp.821-822
- XXVIII. **RESOLVE-IT PHASE 3 TRIAL OF ELAFIBRANOR IN NASH: FINAL RESULTS OF THE WEEK 72 INTERIM SURROGATE EFFICACY ANALYSIS**  
Harrison S. A., Ratziu V., Bedossa P., Dufour J., Kruger F., Schattenberg J. M., Francque S. M., Arrese M., George J., Bugianesi E., et al.  
AASLD The Liver Meeting, Virginia, United States Of America, 13 - 16 November 2020, pp.23
- XXIX. **PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C: DATA FROM THE GLOBAL LIVER REGISTRY (TM)**  
Yu M., El Kassas M., Lam B. P., Esmat G., Fernandez M. C., Ferret M. A. B., Papatheodoridis G., Isakov V. A., Duseja A., YILMAZ Y., et al.  
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72
- XXX. **CLINICAL AND PATIENT-REPORTED OUTCOMES DATA OF NON-ALCOHOLIC FATTY LIVER DISEASE: LONGITUDINAL DATA FROM THE GLOBAL NASH REGISTRY (TM)**  
Younossi Z. M., YILMAZ Y., Yu M., Wong V. W., Castellanos Fernandez M., Isakov V. A., Duseja A., Mendez-Sanchez N., Eguchi Y., George J., et al.  
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72
- XXXI. **THE IMPACT OF CHRONIC HEPATITIS B ON PATIENT-REPORTED OUTCOMES FROM THE GLOBAL LIVER REGISTRY (TM)**  
YILMAZ Y., Yu M., Lam B. P., Ferret M. A. B., Papatheodoridis G., Chan W. K., Duseja A., Alswat K. A., El Kassas M., Hamid S. S., et al.  
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72
- XXXII. **SIGNIFICANT KNOWLEDGE GAP ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN REAL-WORLD PRACTICES: A GLOBAL SURVEY OF HEPATOLOGISTS, GASTROENTEROLOGISTS, ENDOCRINOLOGISTS AND PRIMARY CARE PHYSICIANS**  
Younossi Z. M., Takahashi H., Eguchi Y., YILMAZ Y., El Kassas M., Zheng M., Fang J., Wong V. W., Alswat K. A., Chan W. K., et al.  
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72
- XXXIII. **Comparison of clinical and histological characteristics of biopsyproven non-alcoholic fatty liver patients with and without type 2 diabetes mellitus: 10 years of experience from a single tertiary care center**  
YILMAZ Y.  
APASL 2020 Bali - 29th Annual Conference Asian Pacific Association for the Study of the Liver, Balvi, Latvia, 4 - 08 March 2020, vol.14, pp.1-470
- XXXIV. **THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR)**  
YILMAZ Y.  
Digestive Disease Week, United States Of America, 23 January 2020, vol.158, pp.1269
- XXXV. **CLINICAL AND PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY**  
YILMAZ Y.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.70, pp.577-578
- XXXVI. **SEVERE IMPAIRMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY**

YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.359

**XXXVII. CAN ADVANCED FIBROSIS RELIABLY EXCLUDED BY SIMPLE NON-INVASIVE FIBROSIS SCORING SYSTEMS?: PERFORMANCE OF FIB-4 AND NFS IN A BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE SAMPLE**

YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.70, pp.1053-1054

**XXXVIII. CLINICAL AND PATIENT-REPORTED OUTCOMES DATA FOR PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY**

YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019

**XXXIX. DIFFERENCES IN THE CLINICAL PROFILE OF THE MOST COMMON CAUSES OF CHRONIC LIVER DISEASE (CLD) ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY.**

YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.70, pp.463-465

**XL. USEFULNESS OF ENDOSCOPIC ULTRASONOGRAPHY ELASTOGRAPHY (EUS-E) TO MEASURE LIVER STIFFNESS**

Duman D. G., Alahdab Y., Demirtas C. O., YILMAZ Y., GÜNDÜZ F.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70

**XLII. THE UTILITY OF NONINVASIVE SCORES IN ASSESSING THE ADVANCED HEPATIC FIBROSIS IN TYPE 2 DIABETIC PATIENTS WITH BIOPSY PROVEN NONALCOHOLIC FATTY LIVER DISEASE**

Alkayyali T., Quatranji L., Kaya E., Bakir A., YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70

**XLII. ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH LIVER STIFFNESS IN BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE: A TRANSIENT ELASTOGRAPHY STUDY**

Bilgin B. O., SÜNBÜL M., Kani H. T., Demirtas C. O., KEKLİKKIRAN Ç., YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70

**XLIII. ILver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease**

Sun D., Fun Zhou Y., Kani H. T., Chen Fei Z., Pei Wu Z., Hong Lei M., Wen Yue L., Hao Yang Z., Xiao Dong W., Wei Jie Y., et al.

EASL 2019, Paris, France, 14 April 2019

**XLIV. ILver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease**

Sun D. Q., Ye F., Haluk Tarik K., Zheng C., Zhu P., Ma H., Liu W., Zhang H., Wang X., Yuan W., et al.

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Austria, 10 - 14 April 2019, vol.70

**XLV. Translating NAFLD AASLD data to local practice**

YILMAZ Y.

AASLD TASL Regional Connect Meeting, İstanbul, Turkey, 15 - 16 March 2019

**XLVI. Nonalcoholic Fatty Liver Disease(NAFLD) and Alcoholic Fatty Liver Disease(AFLD): The impact of Alcohol Consumption and Metabolic Syndrome on Mortality**

Younossi Z., Stepanova M., Ong J., Yilmaz Y., Duseja A., Eguchi Y., Kassas M. E., Fernandez M., George J., Jacobson I., et

al.

THE AASLD LIVER MEETING, South-Carolina, United States Of America, 9 - 13 November 2018

**XLVII. Noninvazif Fibrozis ve Yağlanma Ölçümü:Fibroscan/CAP**

YILMAZ Y.

4. Azerbaycan-Türkiye Ortak Hepatoloji Kursu, Bakü, Azerbaycan, 06 October 2018

**XLVIII. Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Fatty Liver Disease (AFLD): The Impact of Alcohol Consumption and Metabolic Syndrome on Mortality**

Younossi Z. M., Stepanova M., Ong J., YILMAZ Y., Duseja A. K., Eguchi Y., El Kassas M., Fernandez M., George J., Jacobson I. M., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Costa Rica, 9 - 13 November 2018, vol.68

**XLIX. Non-alcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma listed for liver transplantation in United States: data from the Scientific Registry of Transplant Recipients**

Younossi Z., Stepanova M., Ong J., Jacobson I., Bugianesi E., Duseja A., Eguchi Y., Wong V., Negro F., YILMAZ Y., et al. Joint International Congress of ILTS, ELITA and LICAGE, Lisbon, Portugal, 23 - 26 May 2018, vol.102, pp.304-305

**L. Transient elastography with controlled attenuation parameter in the assessment of hepatic steatosis and significant liver fibrosis in patients with scleroderma**

Yilmaz Y., Kani H. T., Şahinkaya Y., Mursaloğlu H. H., Aziziy M., İnanç G. N., Direskeneli R. H.

27th Annual Conference of APASL, Dilli, India, 14 - 18 March 2018, vol.12, pp.378

**LI. Tanıdan tedaviye alkole bağlı olmayan yağlı karaciğer hastalığı**

YILMAZ Y.

Bakü 2018 Hepatoloji Sempozyumu, Bakü, Azerbaycan, 21 January 2018

**LII. Karaciğer fibrozisinin değerlendirilmesinde elastografinin rolü**

YILMAZ Y.

Bakü 2018 Hepatoloji Sempozyumu, Bakü, Azerbaycan, 21 January 2018

**LIII. Klinik pratikte transiyent elastografi kullanımı**

YILMAZ Y.

Bakü 2018 Hepatoloji Sempozyumu, Bakü, Azerbaycan, 21 January 2018

**LIV. Preliminary evidence of an association between mtDNA D-loop polymorphisms and the clinicopathological features of nonalcoholic steatohepatitis**

Hasturk B., Yilmaz Y., Eren F.

68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 October 2017, vol.66

**LV. Nonalcoholic steatohepatitis: modulation of histological phenotype by the missense Thr174Met (rs4762) polymorphism of the angiotensinogen (AGT) gene**

EREN F., Balcilar H., Yilmaz D., Toker T., YILMAZ Y., Hasturk B.

68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 October 2017, vol.66

**LVI. Mitochondrial DNA control region nucleotide variations in non-alcoholic steatohepatitis**

Hasturk B., Yilmaz Y., Eren F.

European Biotechnology Congress, Dubrovnik, Croatia, 25 - 27 May 2017, vol.256

**LVII. The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study**

UYGUN A., öztürk k., demirci h., öztuna a., EREN F., KOZAN S., YILMAZ Y., KURT Ö., TÜRKER T., vatansever s., et al.

JOURNAL OF HEPATOLOGY, Amsterdam, Netherlands, 19 - 23 April 2017, vol.66, pp.148

**LVIII. Prevalence of fatty liver in inflammatory bowel disease : a transient elastography study on the basis of a controlled attenuation parameter.**

YILMAZ Y., KANI H. T.

5th Annual Meeting of the Asian Organization for Crohn's and Colitis, Seul, South Korea, 15 - 17 June 2017

**LIX. Prevalence of Fatty Liver in IBD: A Transient Elastography Study on the Basis of a Controlled Attenuation Parameter**

Kani H. T., Demirtas I., Yilmaz Y.

The 5th Annual Meeting of Asian Organization for Crohn's Colitis, Seoul, South Korea, 15 - 17 June 2017, pp.235-236

- LX. **NAFLD: Yeni ne var?**  
YILMAZ Y.  
11. Ulusal Hepatoloji Kongresi, Antalya, Turkey, 17 - 21 May 2017
- LXI. **Hepatit C Tedavilerinin İlaç Etkileşimleri**  
YILMAZ Y.  
Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Turkey, 28 - 29 April 2017
- LXII. **Marmara Üniversitesi Tıp Fakültesi Harvoni Deneyimi**  
YILMAZ Y.  
Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Turkey, 28 - 29 April 2017
- LXIII. **NASH'te yeni ne var?**  
YILMAZ Y.  
14. Ulusal Hepatogastroenteroloji Kongresi, Antalya, Turkey, 5 - 08 April 2017
- LXIV. **Yüzyılın Epidemisi Alkol Dışı Karaciğer Yağlanması Hastalığı**  
YILMAZ Y.  
33. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 22 - 27 December 2016
- LXV. **COMPARİSİON OF DOPPLER ULTRASOUND AND TRANSİENT ELASTOGRAPHY FOR DİAGNOSİS OF SİGNİFİCANT FİBROSİS İN NONALCOHOLİC STEATOHEPATİT**  
ERGELEN R., YILMAZ Y., ASADOV R., CELİKEL Ç., AKIN H., BUGDAYCI O., ALTUN E., TUNEY D.  
ESGAR, 14 - 16 December 2016
- LXVI. **Obezite ve yağlı karaciğer**  
YILMAZ Y.  
7. Ulusal Obezite Kongresi, İstanbul, Turkey, 8 - 11 December 2016
- LXVII. **Sülfasalazin kullanımı sonrası gelişen Dress sendromu Olgu sunumu**  
DURĞAY M., AYKUT U. E., ÖZEN ALAHDAB Y., YILMAZ Y., DEMİR O.  
33. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 22 - 27 November 2016
- LXVIII. **İrritabl barsak sendromlu hastalarda yüksek laktoz intolerans sıklığı**  
hasanov r., ÖZEN ALAHDAB Y., EREN F., GÜNDÜZ F., YILMAZ Y., AYKUT U. E.  
33. Ulusal gastroenteroloji haftası, Turkey, 22 - 27 November 2016
- LXIX. **Türk toplumunda alkolik olmayan yağlı karaciğer hastalığının genetik polimorfizm ile ilişkisi çok merkezli kontrollü çalışma**  
UYGUN A., öztürk k., DEMİRCİ H., öztuna a., EREN F., YILMAZ Y., KOZAN S., KURT Ö., KİLCİLER A. G., vatansever s., et al.  
33. Ulusal gastroenteroloji haftası, Antalya, Turkey, 22 - 27 November 2016
- LXX. **Two atypical forms of Nonalcoholic fatty liver disease NAFLD without metabolic syndrome and Lean NAFLD**  
YILMAZ Y.  
APASL Single Topic Conference, İstanbul, Turkey, 22 - 24 September 2016
- LXXI. **MT ND5 gene variants have both protective and risk factor for inflammatory bowel disease**  
Eren F., Safarova C., Gündüz F., Özen Alahdab Y., Kurt R., Yılmaz Y., Atuş Ö., İmeryüz N., Akın H.  
The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japan, 7 - 09 July 2016
- LXXII. **Bactericidal permeability increasing protein has no effect on remission of ulcerative colitis**  
EREN F., eroğlu k., Banzragch M., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., YILMAZ Y., ATUĞ Ö., İMERYÜZ N., AKIN H.  
The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japan, 7 - 09 July 2016
- LXXIII. **Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis**  
ERGELEN R., YILMAZ Y., ASADOV R., ÇELİKEL Ç., AKIN H., BUGDAYCI O., ALTUN E., TUNEY D.  
European Society of Gastrointestinal and Abdominal Radiology, 14 - 17 June 2016
- LXXIV. **Yağlı Karaciğerde Yeni İlaç Tedavileri**



- YILMAZ Y.  
Klinik Gastroenteroloji Toplantısı-5, İstanbul, Turkey, 02 June 2016
- LXXV. **Kronik Viral Hepatitlerde Non İnvazif Yöntemle Fibrozis Belirleme Algoritmeleri**  
YILMAZ Y.  
Hepatit B Enfeksiyonu Akademisi, Çanakkale, Turkey, 28 May 2016
- LXXVI. **Controlled attenuation parameter and liver stiffness measurements by fibroscan for the detection of non alcoholic fatty liver disease in patients with type 2 diabetes results from a pilot study**  
DURĞAY M., DEYNELİ O., YILMAZ Y.  
EASL monothematic conference 2016, Riga, Latvia, 12 - 14 May 2016
- LXXVII. **Karaciğer Hasarının Değerlendirilmesi Non İnvazif Testlere Algoritmik Yaklaşım**  
YILMAZ Y.  
XIII. Ulusal Viral Hepatit Kongresi, Antalya, Turkey, 17 - 20 March 2016
- LXXVIII. **Alkol Dışı Yağlı Karaciğer Hastalığında Yeni Ne Var**  
YILMAZ Y.  
TKAD Mezuniyet Sonrası Eğitim Sempozyumu: Karaciğerde Çok Yenilik Var:AASLD 2015'den Süzülenler, İstanbul, Turkey, 13 January 2016
- LXXIX. **Karaciğer Fibrozisinde Yeni Non İnvaziv Yöntem ELF Test**  
DURUSOY S. S., ÖZDEMİR F. T., ÖZDOĞAN O. C., RAHMİ A., YILMAZ Y., YEĞİN E. G., AYKUT U. E.  
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- LXXX. **Diyabetik Hastalarda Nonalkolik Yağlı Karaciğer Hastalığının ve Fibrozisin Fibroscan Aracılı CAP ve Karaciğer Sertlik Ölçümü ile Prospektif Taranması Ön Bulgularımız**  
DURĞAY M., DEYNELİ O., YILMAZ Y.  
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- LXXXI. **Does Helicobacter pylori Infection Influences the Complication rate After Sleeve Gastrectomy From an Endemic Region**  
AKYÜZ Ü., ALTUN H., BURÇİN B., YILMAZ Y., DERYA U.  
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- LXXXII. **Ülseratif Kolitin ÜK Hastalık Aktivitesi Bakterisidal Permeabilite Arttırıcı Protein BPI Düzeyi ile İlişkilidir**  
EREN F., EROĞLU K., MUNKHTSETSEG B., ALAHDAB Y. Ö., KURT R., YILMAZ Y., İMERYÜZ N., AKIN H.  
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- LXXXIII. **NASH Patogenezi ve Tedavisinde Yeni Bir Şey Var Mı**  
YILMAZ Y.  
32.Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 25 - 29 November 2015
- LXXXIV. **Ülseratif kolitin hastalık aktivitesi bakterisidal permeabilite arttırıcı protein BPI düzeyi ile ilişkilidir**  
EREN F., eroğlu k., banzragch m., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., YILMAZ Y., ATUĞ Ö., İMERYÜZ N., AKIN H.  
32. Ulusal Gastroenetroloji Haftası, Turkey, 25 - 29 November 2015
- LXXXV. **NAFLD in absence of Metabolic Syndrome**  
YILMAZ Y.  
FRONTIERS IN HEPATOLOGY Non-alcoholic Fatty Liver Disease & the Metabolic Syndrome – Key questions on disease consequences and treatment –, Londrina, Brazil, 24 November 2015
- LXXXVI. **Latent tüberküloz tanısında interferon gamma salınım testi ile tüberkülin deri testinin karşılaştırılması**  
ÖZEN ALAHDAB Y., Kedrah A. E., GÜNDÜZ F., YÖNAL O., YILMAZ Y., ALAHDAB H., HAMZAOĞLU H.  
BUHASDER 6.Tepecik Enfeksiyon Günleri Sempozyumu, Muğla, Turkey, 4 - 08 November 2015
- LXXXVII. **Nonalkolik Yağlı Karaciğerli Hastalarda İleri Evre Fibrozisin Saptanmasında Noninvazif Yeni Bir Yöntem Olan Fibrometer VCTE nin Tanısal Performansı**  
DİNÇSES E., YILMAZ Y.  
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015, vol.26, pp.21
- LXXXVIII. **Aktif Kahverengi Yağ Dokusu Varlığı Yağlı Karaciğer Hastalığı Gelişimini Önlüyor Olabilir**

Salih Ö., Tunç Ö., YILMAZ Y., TUROĞLU H. T., İMERYÜZ N.

32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015, vol.26, pp.43-44

- LXXXIX. **Non alcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with non alcoholic fatty liver disease**  
SÜN BÜL M., KIVRAK T., DURMUŞ E., AKIN H., AYDIN Y., ERGELEN R., YILMAZ Y., AĞIRBAŞLI M. A.  
31. TURKISH CARDIOLOGY CONGRESS WITH INTERNATIONAL PARTICIPATION, 22 - 25 October 2015
- XC. **Can FibroMeter VCTE (TM) be useful for detecting hepatic fibrosis in patients with non-alcoholic fatty liver disease?**  
Dincses E., YILMAZ Y.  
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62
- XC.I. **Can FibroMeter VCTE be useful for detecting hepatic fibrosis in patients with non alcoholic fatty liver disease**  
DİNÇSES E., YILMAZ Y.  
The AASLD Liver Meeting 2015, San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62, pp.1270
- XC.II. **Yeni Antikoagülanlar İşlem öncesi ve sonrası yaklaşım**  
YILMAZ Y.  
3.Gastrointestinal Endoskopi Günleri, İstanbul, Turkey, 8 - 09 May 2015
- XC.III. **Characterization of Lean Patients With Nonalcoholic Fatty Liver Disease Potential Role of High Hemoglobin Levels**  
AKYÜZ Ü., YEŞİL A., YILMAZ Y.  
46th Annual Digestive Disease Week (DDW), Washington, Kiribati, 16 - 19 May 2015, vol.148, pp.1058
- XC.IV. **Noninvasive tests in the diagnosis of Non Alcoholic Fatty Liver Disease**  
YILMAZ Y.  
The 24th Conference of the Asian Pacific Association for the Study of Liver (APASL), İstanbul, Turkey, 12 - 15 March 2015
- XC.V. **Yağlı Karaciğer Non alkolik Steatohepatit ve Alkolik Steatohepatit**  
YILMAZ Y.  
Uludağ İç Hastalıkları Kış Kongresi, Bursa, Turkey, 08 March 2015
- XC.VI. **Hepatoselüler Karsinoma Karsinogenezde endokrin metabolik mekanizmalar**  
YILMAZ Y.  
13. Hepatoloji Sempozyumu, Ankara, Turkey, 17 January 2015
- XC.VII. **Barsak karaciğeri nasıl etkiler**  
YILMAZ Y.  
31. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 24 - 28 November 2014
- XC.VIII. **Otoimmün hepatit ilaç hepatotoksitesisi yağlı karaciğer ve hepatitte yaklaşım ilaç seçimi ve izlem**  
YILMAZ Y.  
A'dan Z'ye Psöriazis Toplantısı, İstanbul, Turkey, 08 November 2014
- XC.IX. **Klinik Araştırma Planlaması**  
YILMAZ Y.  
11. Ulusal HEBİPA Kongresi, Cyprus (Kkct), 24 - 28 September 2014
- C. **Alkol Dışı Yağlı Karaciğer Hastalığı**  
YILMAZ Y.  
1. TÜRKİYE-AZERBAYCAN ORTAK HEPATOLOJİ KURSU, İstanbul, Turkey, 18 - 19 September 2014
- CI. **Biodegradable Stentler**  
YILMAZ Y.  
Türk Gastroenteroloji Derneği İstanbul Şubesi Mezuniyet Sonrası Eğitim Toplantısı, İstanbul, Turkey, 25 June 2014
- CII. **Fibrokistik Karaciğer Hastalıkları**  
YILMAZ Y.  
Türk Karaciğer Araştırmaları Derneği Mezuniyet Sonrası Eğitim Toplantısı, İstanbul, Turkey, 13 June 2014
- CIII. **KC biyopsi Fibroscan uygulamaları**

AYGÜN C., YILMAZ Y.

5. Hepatoloji Okulu, Kocaeli, Turkey, 30 May - 01 June 2014

**CIV. Karaciğer Transplantasyonlu Hastalarda Metabolik Komplikasyonlar ve Sorunların Yönetimi**

YILMAZ Y.

Organ Nakilleri Bilinçlendirme ve Geliştirme Derneği Karaciğer Nakli Mezuniyet Sonrası Eğitim Kursu 1, İstanbul, Turkey, 24 May 2014

**CV. Alkol Dışı Yağlı Karaciğer Hastalıkları**

YILMAZ Y.

İSTAHED Kongresi Viral Hepatitler ve Diğer Hepatobilier hastalıklarda Klinik Yaklaşım Kursu, Antalya, Turkey, 10 May 2014

**CVI. Nonalkolik yağlı karaciğer Nonalkolik steatohepatit**

YILMAZ Y.

Türk Karaciğer Vakfı Mezuniyet Sonrası Eğitim Toplantıları, İstanbul, Turkey, 29 March 2014

**CVII. Erişkinde Yağlı Karaciğer Hastalığı ve Yönetimi Yenilik var mı**

YILMAZ Y.

Karaciğer Hastalıkları ve Transplantasyonu Güncelleme Toplantısı, İstanbul, Turkey, 01 March 2014

**CVIII. Are patients with biopsy proven non alcoholic fatty liver disease at increased risk of asthma Results from a Turkish cross sectional study**

TAŞLI B., YILMAZ Y.

The Asian Pacific Society of Respiratory 19th Congress, Balvi, Latvia, 13 - 16 November 2014, vol.19, pp.173-203

**CIX. Fibroscan aracılı CAP kronik karaciğer hastalıklarında yağlanmanın şiddetini hastalık etyolojisinden ve fibrozisten bağımsız olarak doğru tahmin eder**

YILMAZ Y., YEŞİL A., GERİN F., ERGELEN R., AKIN H., ÇELİKEL Ç., İMERYÜZ N.

30. Ulusal Gastroenteroloji Haftası, Turkey, 11 - 15 October 2013

**CX. CAP yöntemli Fibroscan ile karaciğer yağlanmasının kantitatif değerlendirilmesi Karaciğer biyopsisi ile karşılaştırmalı prospektif çalışma**

YILMAZ Y., YESİL A., GERİN F., ERGELEN R., AKIN H., ÇELİKEL Ç., İMERYÜZ N.

30. Ulusal Gastroenteroloji Haftası, Turkey, 11 - 15 October 2013

**CXI. Evaluation of gallbladder kinetics in patients with nonalcoholic fatty liver disease**

Colak Y., Bozbey G., Senates E., Doganay L., Coskunpinar E., Ozturk O., Mesci B., Kuru I., Tasan G., YILMAZ Y., et al.

64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58

**CXII. NAFLD da Metformin Hiç Vermeyelim mi**

YILMAZ Y.

10.Ulusal Hepato Gastroenteroloji Kongresi, Magosa, Cyprus (Kktc), 25 - 29 September 2013

**CXIII. Mikrobiyota ve Nonalkolik Yağlı Karaciğer Hastalığı**

YILMAZ Y.

30. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 11 - 15 September 2013

**CXIV. HEPATIC EXPRESSION AND SERUM LEVELS OF SYNDECAN 1 (CD138) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE**

Yilmaz Y., Eren F., Colak Y., Senates E., Celikel C. A., Imeryuz N.

International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, vol.58

**CXV. HYPOTHYROIDISM IS NOT ASSOCIATED WITH SPECIFIC HISTOLOGICAL FEATURES OR SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE**

Yilmaz Y., Ayyildiz T., Colak Y., Senates E., Arabul M., Unsal B., Tuncer I., Dolar E.

International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, vol.58

**CXVI. A BIOMARKER PANEL WITH HIGH SENSITIVITY AND SPECIFICITY FOR NONALCOHOLIC STEATOHEPATITIS IDENTIFIED BY SUPPORT VECTOR MACHINE**

Yilmaz Y., Eren F.

International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, vol.58

**CXVII. GALLSTONE DISEASE IS NOT ASSOCIATED WITH LIVER FIBROSIS AND NONALCOHOLIC STEATOHEPATITIS IN NONALCOHOLIC FATTY LIVER DISEASE**

Yilmaz Y., Ayyildiz T., Akin H., Colak Y., Ozturk O., Senates E., Tuncer I., Dolar E.

International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, vol.58

**CXVIII. Metabolik Sendrom ve NAYK Patogenezde Yenilikler**

YILMAZ Y.

11. Hepatoloji Sempozyumu, Ankara, Turkey, 18 - 19 January 2013

**CXIX. NAFLD patogenezinde yeni ne var Steatoz koruyucu bir mekanizma mıdır**

YILMAZ Y.

29. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 20 - 25 November 2012

**CXX. NASH Tedavisinde Yenilikler**

YILMAZ Y.

9. Ulusal HepatoGastroenteroloji Kongresi, Magosa, Cyprus (Kktc), 26 - 30 September 2012

**CXXI. Non viral Hepatoselüler Kanser Etyolojisi NAFLD Alkol ve Diğer Faktörler**

YILMAZ Y.

4. Hepatoloji Okulu, Muğla, Turkey, 25 - 26 May 2012

**CXXII. Patogenezde VAT mı önemli SAT mı Günlük yaşamda fruktoz sanıldığı kadar suçlu mu**

YILMAZ Y.

NAFLD Sempozyumu, Ankara, Turkey, 24 March 2012

**CXXIII. Association of MDRI Gene and Helicobacter pylori in the Development of Gastric Cancer and Gastritis**

Eren F., Imeryuz N., Bas E., Ozkan N., Ozdemir F. T., Yilmaz Y., Celikel C. A., Avsar E., Tozun N. A., Ozer A.

Conference on Digestive Disease Week 2011, Illinois, United States Of America, 7 - 10 May 2011, vol.140

**CXXIV. CIRCULATING LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF) AND ITS SOLUBLE RECEPTOR SVEGFR-1 IN PATIENTS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE**

Yilmaz Y., Alahdab Y. O., Kurt R., Yonal O., Eren F., Kalayci C., Avsar E.

46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Germany, 30 March - 03 April 2011, vol.54

**CXXV. SERUM LEVELS OF OSTEOPROTEGERIN IN THE SPECTRUM OF NONALCOHOLIC FATTY LIVER DISEASE**

Yilmaz Y., Yonal O., Kurt R., Eren F., Imeryuz N., Kalayci C., Avsar E.

46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Germany, 30 March - 03 April 2011, vol.54

**CXXVI. PLASMA LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (SRAGE) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE**

Yilmaz Y., Ulukaya E., Gul O. O., Arabul M., Gul C. B., Atug O., Oral A. Y., Dolar E.

44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Copenhagen, Denmark, 22 - 26 April 2009, vol.50

## Activities in Scientific Journals

HELIYON, Assistant Editor/Section Editor, 2023 - Continues

Hepatology Forum, Assistant Editor/Section Editor, 2020 - Continues

Alimentary Pharmacology & Therapeutics, Committee Member, 2020 - Continues

## Memberships / Tasks in Scientific Organizations

## Scientific Refereeing

TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, September 2020  
GASTROENTEROLOGY RESEARCH AND PRACTICE, SCI Journal, September 2020  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, September 2020  
International Journal of Medical Arts, Journal Indexed in ESCI, September 2020  
ARCHIVES OF MEDICAL RESEARCH, SCI Journal, August 2020  
İSTANBUL TIP FAKÜLTESİ DERGİSİ, National Scientific Refreed Journal, August 2020  
BIOMED RESEARCH INTERNATIONAL, Journal Indexed in SCI-E, August 2020  
JOURNAL OF DIABETES AND ITS COMPLICATIONS, Journal Indexed in SCI-E, August 2020  
HEPATOBIILIARY SURGERY AND NUTRITION, SCI Journal, July 2020  
JGH Open, Journal Indexed in ESCI, July 2020  
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, National Scientific Refreed Journal, July 2020  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, July 2020  
DIABETES RESEARCH AND CLINICAL PRACTICE, Journal Indexed in SCI-E, July 2020  
Clinical and Molecular Hepatology, Journal Indexed in ESCI, July 2020  
CHINESE MEDICAL JOURNAL, Journal Indexed in SCI-E, June 2020  
BMC GASTROENTEROLOGY, SCI Journal, June 2020  
CANADIAN JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, May 2020  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, May 2020  
Exploration of Medicine, Other Indexed Journal, May 2020  
LIVER INTERNATIONAL, SCI Journal, March 2020  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, March 2020  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, July 2019  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, June 2019  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, May 2019  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, March 2019  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, February 2019  
LIVER INTERNATIONAL, SCI Journal, November 2016  
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, SCI Journal, November 2016  
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, October 2016  
LIVER INTERNATIONAL, SCI Journal, September 2015  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, July 2015  
JOURNAL OF HEPATOLOGY, SCI Journal, June 2015  
JOURNAL OF HEPATOLOGY, SCI Journal, June 2015  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, May 2015  
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, April 2015  
LIVER INTERNATIONAL, SCI Journal, August 2014  
LIVER INTERNATIONAL, SCI Journal, June 2014  
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, SCI Journal, April 2013

## Scientific Research / Working Group Memberships

Yağlı Karaciğer Çalışma Grubu, Türk Karaciğer Araştırmaları Derneği, Turkey, <http://www.tasl.org.tr/>, 2020 - Continues  
The Global Nash Council, Center for Outcomes Research in Liver Diseases, Turkey, <https://www.corld.org/global-nash-council/>, 2018 - Continues

The Global Liver Registry, Center For Outcomes Research in Liver Diseases, Turkey, <https://www.corld.org/global-liver->

## Metrics

Publication: 430

Citation (WoS): 8216

Citation (Scopus): 10555

H-Index (WoS): 39

H-Index (Scopus): 42

## Congress and Symposium Activities

AASLD Annual Meeting, Working Group, Massachusetts, United States Of America, 2019

World Congress of Gastroenterology, Invited Speaker, İstanbul, Turkey, 2019

The NAFLD Summit 2019, Working Group, Sevilla, Spain, 2019

International Conference on Fatty Liver,, Working Group, Berlin, Germany, 2019

Working Group, California, United States Of America, 2019

The EASL International Liver Congress, Working Group, Vienna, Austria, 2019

17th Euroasian Congress of Hepato-Gastroenterology and Surgery, Invited Speaker, Split, Croatia, 2019

AASLD TASL Regional Connect Meeting, Invited Speaker, İstanbul, Turkey, 2019

Asian Pacific Association for the Study of the Liver Annual Meeting, Working Group, Manila, Philippines, 2019

Global NASH Council Meeting, Invited Speaker, California, United States Of America, 2018

APASL Single Topic Conference, Invited Speaker, İstanbul, Turkey, 2016

FRONTIERS IN HEPATOLOGY Non-alcoholic Fatty Liver Disease & the Metabolic Syndrome – Key questions on disease consequences and treatment , Invited Speaker, London, United Kingdom, 2015

## Awards

Yılmaz Y., 'Dünyanın En Etkili Bilim İnsanları Listesi'nde Türkiye'den Gastroenteroloji alanındaki tek kişi, Plos Biology, July 2020

Eren F., Yılmaz Y., Hayat Bulan Fikirler Proje Destek Ödülü, Gilead, November 2019

Yılmaz Y., Eren F., Hayat Bulan Fikirler Proje Destek Ödülü, Gilead, November 2018

Yılmaz Y., Tıp Bilimine Yön Veren 100 Türk, Turkishtime, September 2018

Yılmaz Y., Hayat Bulan Fikirler Proje Destek Ödülü, Gilead, November 2017

Yılmaz Y., En Yüksek Atıf Ödülü, Marmara Üniversitesi, January 2013

Yılmaz Y., Bayındır Tıp Teşvik Ödülü, Bayındır Holding, January 2012

Yılmaz Y., En Fazla Bilimsel Yayın Puanına Sahip Hekim Ödülü, İstanbul İl Sağlık Müdürlüğü, January 2011

Yılmaz Y., Sağlık Bilimleri Alanında En Yüksek Yayın Performans Ödülü, Marmara Üniversitesi, January 2011

Yılmaz Y., Eczacıbaşı Bilim Teşvik Ödülü, Eczacıbaşı Holding, January 2011

Yılmaz Y., Üstün Başarı Ödülü, Marmara Üniversitesi Tıp Fakültesi, January 2010

Yılmaz Y., Yayın Özel Ödülü, Uludağ Üniversitesi, January 2009

Yılmaz Y., Zafer Paykoç Ödülü, Türkiye Hepatoloji Vakfı, January 2007